Northwestern Journal of Technology and Intellectual Property
Volume 10 | Issue 3

Article 4

Winter 2012

Claiming Nanotechnology: Improving USPTO
Efforts at Classification of Emerging Nano-Enabled
Pharmaceutical Technologies
Jordan Paradise
Seton Hall University School of Law

Recommended Citation
Jordan Paradise, Claiming Nanotechnology: Improving USPTO Efforts at Classification of Emerging Nano-Enabled Pharmaceutical
Technologies, 10 Nw. J. Tech. & Intell. Prop. 169 (2012).
https://scholarlycommons.law.northwestern.edu/njtip/vol10/iss3/4

This Article is brought to you for free and open access by Northwestern Pritzker School of Law Scholarly Commons. It has been accepted for inclusion
in Northwestern Journal of Technology and Intellectual Property by an authorized editor of Northwestern Pritzker School of Law Scholarly Commons.

N O R T H W E S T E R N
JOURNAL OF TECHNOLOGY
AND

INTELLECTUAL PROPERTY

Claiming Nanotechnology: Improving USPTO Efforts at
Classification of Emerging Nano-Enabled Pharmaceutical
Technologies
Jordan Paradise

January 2012
© 2012 by Northwestern University School of Law
Northwestern Journal of Technology and Intellectual Property

VOL. 10, NO. 3

Copyright 2012 by Northwestern University School of Law
Northwestern Journal of Technology and Intellectual Property

Volume 10, Number 3 (January 2012)

Claiming Nanotechnology: Improving USPTO
Efforts at Classification of Emerging NanoEnabled Pharmaceutical Technologies
By Jordan Paradise*
I. INTRODUCTION
¶1

¶2

¶3

Touted as ushering in “the next industrial revolution”1 over ten years ago,
nanotechnology is now positioned to enable tremendous advances in virtually limitless
scientific and technological fields. Unique and novel properties at the nanoscale have
powered innovations in medicine and health care, environmental remediation, electronics,
mechanics, energy, optics, computing and information technology, industrial
manufacturing, and a vast array of marketed consumer goods.
However, as
nanotechnologies advance, so do a barrage of familiar questions that have vexed past
technologies such as biotechnology, genetics, and stem cell research: how should
knowledge and applications of the science and technology be integrated into marketed
products, how will consumers access information about these products, how and to what
extent should resulting inventions be protected, and who will serve as the gatekeeper?
The unique and far-ranging properties of nanostructures and nanotechnologies have
particularly facilitated breakthroughs in the pharmaceutical and medical device realms.
The interface of nanotechnology, biotechnology, and genetics have increased
bioavailability, introduced more precise targeted drug delivery and release, decreased
adverse side effects, and enabled cutting-edge cancer treatments. Due to the high-stakes
characteristics of the pharmaceutical industry—national and multinational corporations,
high upfront research and development costs, rigorous clinical trials and data
requirements, a thriving generic drug market, and intense competition—patents are
particularly critical to innovation and market protection.2
Not surprisingly, innovations at the intersection of nanotechnology and medicine
have inundated the United States Patent and Trademark Office (USPTO) with the
resulting patent applications. Patents that couple genetic sequence information,
*

J.D.; Associate Professor of Law, Seton Hall University School of Law. E-mail:
jordan.paradise@shu.edu. The author would like to thank John Jacobi and David Opderbeck for helpful
feedback on drafts. Special thanks also to Katherine Matos, Joseph Jakas, and Ethan Fitzpatrick for
excellent research assistance. This Article was generously supported by a summer research stipend from
Seton Hall University School of Law.
1
See, e.g., Press Release, White House, National Nanotechnology Initiative: Leading to the Next Industrial
Revolution (Jan. 21, 2000), http://clinton4.nara.gov/WH/New/html/20000121_4.html.
2
See Jordan Paradise, The Devil Is in the Details: Health Care Reform, Biosimilars, and Implementation
Challenges for the Food and Drug Administration, 51 JURIMETRICS J. 279 (2011) [hereinafter Paradise, The
Devil Is in the Details]; Jordan Paradise, Reassessing ‘Safety’ for Nanotechnology Combination Products:
What Do ‘Biosimilars’ Add to Regulatory Challenges for the FDA?, 56 ST. LOUIS U. L.J. (forthcoming
Dec. 2011).
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biological information, and the enabling properties at the nanoscale for diagnosis,
treatment, and long-term patient assessment are the next frontier in health care and
medicine. Along with great promise, nanotechnology innovations undoubtedly signal
looming patent battles as products reach the market.3 As the U.S. health care model
moves toward targeted and personalized medicine utilizing emerging technological
advances, where drugs and medical interventions are tailored to individual biological
make-up and genetic propensity, the pharmaceutical industry will need patent protections
more than ever to stake out product identity and market share.
Recognizing the scope and commercial importance of nanotechnology, the USPTO
has implemented a nanotechnology classification in a laudable effort to foster consistent
categorization in the review of patent applications and maintain an organized storehouse
of issued patents that involve nanotechnology. Developed in 2004, this classification
spans 263 subclasses pertaining to inventions
related to research and technology development at the atomic, molecular or
macromolecular levels, in the length of scale of approximately 1–100 nanometer
range in at least one dimension, and that provide a fundamental understanding of
phenomena and materials at the nano-scale and to create and use structures,
devices and systems that have novel properties and functions because of their
size.4

¶5

¶6

As of May 31, 2011, the USPTO reports over 6,930 issued patents and over 8,725
pending patent applications classified as nanotechnology-related inventions.5
While undoubtedly helpful for internal purposes, the USPTO’s nanotechnology
classification system merely groups patents together to ease prior art searches undertaken
by patent examiners. The classification fails to assess relationships among and between
these patents; identify potentially overlapping and infringing claims; and communicate
information to critical stakeholders, including industry, consumers, and other regulatory
agencies. It also leaves discretion to individual patent examiners to reassess and
reclassify previously issued patents (before 2004) to determine if they are appropriate for
the recently implemented nanotechnology classification. Problems of overlapping claims
and complicated scientific aspects that arise will largely be left to courts to sort out—a
clumsy forum for determination of complex patent law issues that arise based on scale,
size, and interactions at the nanoscale that transcend previously envisioned physical and
chemical boundaries.
Specifically, the USPTO and courts will increasingly face three core problems
involving nanotechnology: (1) limitations of and inconsistencies among current
definitions of nanotechnology; (2) uncertainty and lack of uniformity in measurement
capabilities regarding critical aspects of size, properties, and characteristics at the
3

See discussion infra Part III-B.
Class 977 Nanotechnology Cross-Reference Art Collection, U.S. PAT. & TRADEMARK OFF.,
http://www.uspto.gov/web/patents/biochempharm/crossref.htm (last updated Mar. 18, 2010).
5
USPTO Patent Full-Text and Image Database, U.S. PAT. & TRADEMARK OFF.,
http://patft.uspto.gov/netahtml/PTO/search-adv.htm (search “Query” for “ccl/977/$”) (search last
conducted May 31, 2011); Patent Application Full Text and Image Database, U.S. PAT. & TRADEMARK
OFF., http://appft1.uspto.gov/netahtml/PTO/search-adv.html (search “Query” for “ccl/977/$”) (search last
conducted May 31, 2011).
4
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nanoscale; and (3) the role of patent claims to accurately and consistently encapsulate and
distinguish the scope of nanotechnology inventions. Although pressing, the first two
problems apply across all scientific disciplines and federal regulatory agencies confronted
with emerging applications of nanotechnology. This Article touches on these first two
problems in a broad context, but it focuses on the third problem as positioned against the
function and activities of the USPTO. Given the recent interest of the Supreme Court in
questions of patentability and appropriate claim scope of genetic inventions,6 the time is
ripe for the USPTO to extract lessons for nanotechnology. Honing in on U.S. patent law,
policy, and the current practice of the USPTO, as well as the effect of judicial review in
shaping case law in scientific and technical areas, this Article extracts general lessons and
extrapolates those lessons to the emerging realm of nanopharmaceuticals. While courts
have yet to confront these issues on a regular basis, one particular case is useful in
examining how nanotechnology patents may play out in courts.
This Article utilizes the recent district court case Elan Pharma International, Ltd. v.
Abraxis Bioscience,7 which involved a blockbuster nanotechnology cancer treatment, to
illustrate inherent problems with the USPTO nanotechnology patent classification system
and patent claim scope. Part II discusses the patent system and the USPTO, highlighting
statutory provisions relevant to nanotechnology and identifying informative cases that
apply and interpret those provisions. Part III examines the USPTO response to
nanotechnology, tracing the development of the 977 patent classification system and
identifying where clarification is needed from the USPTO and courts as nanopatenting
progresses. Part IV discusses Elan Pharma, tying it to the three problems identified
above and to the scientific and technical aspects of nanotechnology in the pharmaceutical
realm. Part IV also analyzes both the Elan Pharma patent involved in the case and the
subsequent patent awarded to Abraxis Bioscience following the case and attempts to
reconcile the two. Part V suggests a research agenda to assist the USPTO in fulfilling its
mission to foster and reward innovation, while also assisting in broader efforts to gather
nanotechnology information.
These suggestions include improving the existing
nanotechnology classification process, increasing feedback and collaboration with other
federal agencies relevant to nanotechnology inventions, instituting independent
educational programs for patent examiners, and utilizing new pilot peer review pathways
for nanotechnology applications to encourage broader dialogue on the scope of patent
claims and relationships to already issued patents. Part VI concludes.
II. THE USPTO AND PATENT RIGHTS FOR INVENTIONS

¶8

Article I, Section 8, Clause 8 of the Constitution grants Congress the power “[t]o
promote the Progress of Science . . . by securing for limited Times to . . . Inventors the
exclusive Right to their . . . Discoveries.”8 The USPTO, first established as a
governmental bureau in 1802, is now within the Department of Commerce. Congress
vested authority in the USPTO to review and award patents within the confines of the
U.S. Patent Code9 and USPTO regulations10 and to disseminate patent-related
6

See discussion infra Part II-A-1.
No. 06-438 GMS, 2007 WL 6382930 (D. Del. Dec. 17, 2007).
8
U.S. CONST. art. 1, § 8, cl. 8.
9
35 U.S.C. §§ 1–376 (2006).
7
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information to the public.11 This Part describes the traditional role of the USPTO in
granting patent protections for inventions, highlights general patent requirements, and
discusses legal precedent focusing on advancements in genetics that may pose future
challenges for emerging nanopharmaceutical developments. It also examines the
characteristics of pharmaceutical patents given the statutory schemes for generic drug
development and approval by the Food and Drug Administration (FDA).
A. Patent Requirements and Case Law
¶9

Patent law sets forth four general areas of invention: processes, machines,
manufactures, and compositions of matter.12 In return for the public disclosure of an
invention,13 the applicant is rewarded with exclusive rights to the invention for twenty
years from the date that the application was filed with the USPTO.14 The patent then
gives the patent holder “the right to exclude others from making, using, offering for sale,
or selling the invention throughout the United States or importing the invention into the
United States.”15
¶10
Patent law is not technology specific. The federal patent statute,16 USPTO
regulations,17 and internal USPTO policies and procedures18 all apply to nanotechnologyrelated inventions as they do to inventions in any other technological field. Absent
direction from the USPTO or courts, examiners must review nanotechnology patents by
applying the substantive requirements for patentability set out in 35 U.S.C. § 101
(utility), § 102 (novelty), § 103 (nonobviousness), and § 112 (specification) and must
assure all other patent requirements in Title 35 are fulfilled. Due to the evolving nature
of the understanding of the science and technologies involved, questions remain about the
application by the USPTO and courts of the substantive requirements to nanotechnology,
as well as the foundational issue of patentable subject matter. This Part examines these
concerns as linked to specific provisions in the patent law19 and addresses recent case law
that may impact nanotechnology in the future.

10

Id. § 2(b)(2).
Id. § 2(a)(1), (2).
12
Id. § 101. The USPTO defines process as a “process, act or method, and primarily includes industrial or
technical processes”; machine as “need[ing] no explanation”; manufacture as “articles that are made, and
includes all manufactured articles”; and compositions of matter as “relat[ing] to chemical compositions and
may include mixtures of ingredients as well as new chemical compounds.” U.S. PATENT & TRADEMARK
OFFICE, GENERAL INFORMATION CONCERNING PATENTS 2–3 (2011), available at
http://www.uspto.gov/patents/resources/general_info_concerning_patents.pdf. These four categories
“taken together include practically everything that is made by man and the processes for making the
products.” Id.
13
35 U.S.C. § 112.
14
Id. § 154(a)(2). Where a patent application was submitted prior to June 8, 1996, the term of exclusive
rights extends seventeen years from the application filing date. MPEP § 2701 (8th ed. Rev. 2, May 2004).
15
35 U.S.C. § 154(a)(1).
16
Id. §§ 1–376.
17
37 C.F.R. §§ 1–150 (2010).
18
See, e.g., MPEP (8th ed. Rev. 8, July 2010).
19
This examination of patent law is admittedly only a cursory snapshot of the core provisions and case law
in the interest of length.
11
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1. Patentable Subject Matter
¶11

As the Supreme Court has identified through case law spanning over a century, the
threshold question for determining patentability is whether the invention claims “laws of
nature, physical phenomena, and abstract ideas.”20 If the claimed invention falls into one
of these three broad categories, it is outside the scope of patentable subject matter as a
foundational determination before even reaching issues of utility, novelty,
nonobviousness, and specification. Anything falling within these three categories is “part
of the storehouse of knowledge of all men . . . free to all men and reserved exclusively to
none.”21 Supreme Court case law tracing back to 1874 instructs that merely removing
natural sources from a naturally occurring material does not make it a new composition
of matter or article of manufacture worthy of patent protection because the primary
characteristics and functioning of the product do not significantly differ from what
already exists in nature.22 Case law involving abstract ideas teaches that the USPTO
cannot issue patents for principles in the abstract, which are akin to fundamental truths.23
There must be some tangible process tied to the formula or idea that moves it into the
realm of patentability.24
¶12
Two recent high profile Supreme Court decisions tackling these boundaries of
patentability:25 the Federal Circuit’s highly anticipated July 29, 2011 decision regarding
20

Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
22
Am. Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. (23 Wall.) 566, 584 (1874). Subsequent cases
exploring similar questions of physical phenomenon and products of nature relating to claimed inventions
for compositions of matter or articles of manufacture include Funk Brothers Seed Co., 333 U.S. 127
(combinations and mixtures of root nodule bacteria were not patentable where they served as packaging
function and bacteria still performed in their natural way); Cochrane v. Badische Anilin & Soda Fabrik,
111 U.S. 293 (1884) (synthetic version of alizarine, a dye already existing in nature, imbued with a brighter
hue was not patentable subject matter because it was a known product of nature); Merck & Co. v. Olin
Mathieson Chemical Corp., 253 F.2d 156 (4th Cir. 1958); General Electric Co. v. De Forest Radio Co., 28
F.2d 641 (3d Cir. 1928) (ductility and high tensile strength of purified tungsten making it pliable at room
temperature were characteristics given by nature, not the inventor, and thus not patentable); In re Merz, 97
F.2d 599 (C.C.P.A. 1938) (purified ultramarine dye unpatentable even though produced with new process
creating brighter hue); In re Marden (Marden II), 47 F.2d 958, 959 (C.C.P.A. 1931) (patent for purified
vanadium exhibiting increased ductility and malleability denied because it was a product of nature and
“nothing more or less than vanadium freed from all of its impurities”); In re Marden (Marden I), 47 F.2d
957 (C.C.P.A. 1931) (purified uranium with increased ductility not patentable because it was a purified
form of a product of nature; the court found the process, but not the composition, patentable); and Ex parte
Latimer, 1889 Dec. Comm’r Pat. 123 (holding that purified pine needle fiber derived from Pinus australis
was not patentable as a new article of manufacture for use in textiles).
23
Gottschalk v. Benson, 409 U.S. 63, 67 (1972) (citing Le Roy v. Tatham, 55 U.S. (14 How.) 156, 175
(1852)).
24
The chronological trilogy of cases on this point are Gottschalk, 409 U.S. 63 (algorithm to convert binarycoded decimal numerals into pure binary code not patentable because not a process but an abstract idea);
Parker v. Flook, 437 U.S. 584, 590 (1978) (claiming process for monitoring conditions during catalytic
conversion process in petrochemical and oil-refining industries not a patentable process because “postsolution activity” does not alone transform an unpatentable principle into a patentable process); and
Diamond v. Diehr, 450 U.S. 175 (1981) (claims to previously unknown method for molding raw, uncured,
synthetic rubber into cured precision products using a mathematical formula to complete some of the steps
with a computer is patentable, as it patents an industrial process rather than the mathematical formula).
25
These two cases are Bilski v. Kappos, 130 S. Ct. 3218 (2010), and Laboratory Corp. of America
Holdings v. Metabolite Laboratories, 548 U.S. 124 (2006) (per curiam). Bilski involved patent claims
21
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the patentability of genetic sequences26 and the recent grant of certiorari to examine
whether diagnostic tests that correlate results and patient health are phenomena of
nature27 pose questions for nanotechnology patents. Although outside the scope of this
Article, this collection of cases signals past and present struggles by courts and the
USPTO to apply bright-line rules to determine whether a claimed invention is not patent
eligible as a law of nature, physical phenomenon, or abstract idea. This is surely
informative for nanotechnology as patenting trends continue; aside from litigation
involving allegations of patent infringement for a nanotechnology patent, there may also
be challenges to USPTO (and Patent Board of Appeals) determinations of ineligibility
that make their way to the Federal Circuit and Supreme Court. To be sure,
nanotechnology products and inventions will inevitably cross all scientific and technical
areas that have thus far raised questions in terms of patentable subject matter and laws of
nature, physical phenomenon, and abstract ideas.
2. Utility
¶13

In addition to enumerating the four technological categories of patentable subject
matter, § 101 also requires that an inventor show that the claimed invention is “useful.”
As discussed in the context of patentable subject matter, “[w]hoever invents or discovers
any new and useful process, machine, manufacture, or composition of matter, or any new
and useful improvement” may obtain a patent, subject to the conditions of the application

related to the interaction of commodities buyers and sellers and methods of hedging against the risk of price
fluctuations using a mathematical formula. Bilski, 130 S. Ct. at 3223. The Federal Circuit had previously
applied the machine-or-transformation test and found the invention is not patentable subject matter. In re
Bilski, 545 F.3d 943, 964 (Fed. Cir. 2008). The court held that “[a] claimed process is surely patenteligible under § 101 if: (1) it is tied to a particular machine or apparatus, or (2) it transforms a particular
article into a different state or thing.” Id. at 954. In Metabolite, the majority ultimately dismissed the writ
of certiorari as improvidently granted following oral arguments. Metabolite Labs., 548 U.S. at 125. The
patent claim covered not only the action of assaying body fluid samples to measure homocysteine levels,
but also the action of correlating the assay result to a vitamin deficiency. Id. at 129 (Breyer, J., dissenting).
However, the strong dissent by Justice Breyer foreshadows future attention from the Court. Examining
precedent and the scope of the patent claim, Breyer concluded that the patent was invalid as an
unpatentable natural phenomenon. Id. at 137 (citing Flook, 437 U.S. at 588 n.9).
26
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011). The
panel reversed the district court’s decision that the composition claims to “isolated” DNA molecules
claiming BRCA1 and BRCA2 genes cover patent-ineligible products of nature under 35 U.S.C. § 101
because the molecules as claimed do not exist in nature. Id. at 1334, 1342. It reversed the decision that the
method claim to screening potential cancer therapeutics via changes in cell growth rates is directed to a
patent-ineligible scientific principle and affirmed the decision that method claims directed to “comparing”
or “analyzing” DNA sequences are patent ineligible, reasoning that they include no transformative steps
and cover abstract mental steps and are thus patent ineligible. Id. at 1334.
27
The Supreme Court granted certiorari on June 20, 2011. Prometheus Labs., Inc. v. Mayo Collaborative
Servs., 628 F.3d 1347 (Fed. Cir. 2010), cert. granted, 131 S. Ct. 3027 (2011). The patents at issue in
Prometheus claim blood level measurement and assessment methods coupled with correlation of patient
blood levels, patient health, and proper dosage of thiopurine drugs for treatment of “gastrointestinal and
non-gastrointestinal autoimmune diseases.” Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d
1336, 1339 (Fed. Cir. 2009). The Federal Circuit originally held the claims patentable and valid in 2009
based on the machine-or-transformation test. Id. The Federal Circuit upheld that decision in December
2010. Prometheus Labs., 628 F.3d at 1347.
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requirements.28 An inventor must show that the invention has a specific, substantial, and
credible utility where credibility is measured from the perspective of one skilled in the
art.29 This inquiry also ties into the § 112 specification assessment, discussed below,
which requires a description of how to make and use the invention. Given the fact that
the USPTO rarely invokes the utility requirement as grounds for denying a patent (and
accused infringers rarely hinge a legal defense on it),30 it is similarly unlikely to be a
hurdle for nanotechnology patents. By its very nature, nanotechnology introduces
characteristics and functions not observed at the macro scale or micro scale that lead to
new uses based on those characteristics and functions.
Both the National
Nanotechnology Initiative (NNI) definition and the USPTO definition instruct that the
size is not the only aspect to be considered; the novel features that result, as well as the
ability to control and manipulate at that size, are also critical.31
3. Novelty
¶14

Novelty is generally described as what it does not include. An invention is not
novel if it was: (1) known or used by others, patented, or described in a printed
publication prior to the invention by the patent applicant;32 (2) in public use or on sale for
over a year prior to the date of the application;33 (3) abandoned by the inventor;34 (4)
patented for more than a year prior to the U.S. application in a foreign country;35 (5)
described in another patent;36 (6) not invented by the applicant (as in the case of theft);37
or (7) made by a person other than the applicant or assignee.38 Case law offers that “there
can be no hard and fast rule” to determine novelty and each case must be examined on a
case-by-case basis;39 but, essentially, an invention must accomplish something new to
satisfy the substantive novelty requirements.
¶15
Claims based on the novel properties of nanotechnology inventions often
distinguish new claims from prior art due to the different features, characteristics, and
properties at the nanoscale that did not exist at the macro scale. Nanotechnology
inventions often exhibit unexpected, size-dependent properties that result in the very
novelty of the invention. For example, gold nanoparticles (approximately 13 nm in
diameter) have fluorescent properties not present at a larger scale, and their ability to bind
to DNA make them excellent sensors to detect and image life-threatening viruses and
bacteria.40 One such detection system reports ten times the sensitivity and 100,000 times

28

35 U.S.C. § 101 (2006).
Utility Examination Guidelines, 66 Fed. Reg. 1092, 1097 (Jan. 5, 2001).
30
MARTIN J. ADELMAN ET AL., CASES AND MATERIALS ON PATENT LAW 181 (1st ed. 1998).
31
See discussion infra Part III.
32
35 U.S.C. § 102(a).
33
Id. § 102(b).
34
Id. § 102(c).
35
Id. § 102(d).
36
Id. § 102(e)(2).
37
Id. § 102(f).
38
Id. § 102(g)(2).
39
Union Carbide Co. v. Am. Carbide Co., 181 F. 104, 106 (2d Cir. 1910).
40
KEWAL K. JAIN, THE HANDBOOK OF NANOMEDICINE 69–70 (2008).
29
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the specificity of genomic detection systems currently in use.41
Because the
nanotechnology definition implemented by the USPTO requires size-dependent
properties to be included in the 977 Class,42 patent applicants must include some indicia
of inclusion into that size range that results in a novel property exhibited by the claimed
invention.
¶16
Two century-old cases demonstrate courts’ long-standing view regarding novelty
and are relevant to nanotechnology. Both cases involve a new form of an already known
man-made substance that gave the invention an increased commercial or therapeutic
value. In one, the inventor laid claim to a man-made substance, calcium carbide, in
crystalline form when it was previously only available in a man-made amorphous form.43
The Second Circuit held that a “[m]ere change of form in and of itself does not disclose
novelty”44 but could be based on superior efficiency, durability, purity, or other
comparative aspects that gave the invention commercial benefit.45 Similarly, the Seventh
Circuit held that aspirin—a purified, crystallized version of acetyl salicylic acid (a manmade substance)—was patentable because, although it is chemically the same, after it is
heated with acetic anhydride to produce a crystallized form, it holds a tight bond while
passing through the acidic fluids of the stomach and releases effectively in the intestines.
This increases the therapeutic effect.46 The court noted that “a chemical formula is
simply the symbolical expression of the composition or constitution of a substance . . . .
That is to say, two substances, having the same chemical formula, may differ widely, as
to impurities, upon qualitative analysis.”47 Subsequent cases have echoed this view.48
4. Nonobviousness
¶17

Logically tied to concepts of novelty, patent applications can also be rejected by
patent examiners on grounds of obviousness, where patent examiners conduct a
comparison of the invention to what is already in the public domain, termed the prior art.
If the patent examiner determines that the differences between the scope and content of
subject matter in the application and the prior art renders the subject matter as a whole
obvious at the time of invention to a “person having ordinary skill in the art,” it will be
deemed obvious and unable to acquire patent protection.49
¶18
In a recent trend, the USPTO and the Federal Circuit have construed obviousness
by applying the “teaching, suggestion, or motivation” (TSM) test. Under this test, an
invention is obvious if the “the prior art, the problem’s nature, or the knowledge of a
person having ordinary skill in the art reveals some motivation or suggestion to combine
41

So-Jung Park et al., Array-Based Electrical Detection of DNA with Nanoparticle Probes, 295 SCIENCE
1503 (2002).
42
See discussion infra Part III.
43
Union Carbide, 181 F. at 105.
44
Id. at 106.
45
Id. at 106–07.
46
Kuehmsted v. Farbenfabriken of Elberfeld Co., 179 F. 701 (7th Cir. 1910).
47
Id. at 703–04.
48
See, e.g., Lori Andrews & Jordan Paradise, Genetic Sequence Patents: Historical Justification and
Current Impacts, in MAX PLANCK INST. FOR THE HISTORY OF SCI., LIVING PROPERTIES: MAKING
KNOWLEDGE AND CONTROLLING OWNERSHIP IN THE HISTORY OF BIOLOGY 137, 151–52 (Jean-Paul
Gaudillière et al. eds., 2009) (discussing cases addressing the issue of gene patenting).
49
35 U.S.C. § 103(a) (2006).
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the prior art teachings.”50 The Supreme Court clarified the scope of the TSM test in KSR
v. Teleflex, holding that the narrow, rigid manner of evaluating obviousness under the
TSM test is inconsistent both with § 103 and with the Court’s precedent.51 Referencing
the 1966 case Graham v. John Deere Co. of Kansas City,52 the Court reiterated the need
for an expansive and flexible approach in which the inquiry is not limited to the TSM
test, but considers whether the improvement to the prior art is more than “the predictable
use of prior art elements according to their established functions.”53 Although the Court
stated that the TSM test “captured a helpful insight” that a patent is nonobvious merely
because each element of the patent was independently known in the prior art, it should
not become a rigid and mandatory formula.54 The USPTO, the Board of Patent Appeals
and Interferences, and the Federal Circuit will be attempting to apply this expansive view
of the obviousness inquiry to all areas of invention in the coming years.55
¶19
The USPTO appears to maintain the position that claim limitations related to size
or scale are insufficient to overcome prior art.56 The USPTO relies on the 1955 U.S.
Court of Customs and Patent Appeals case of In re Rose57 to support its position that the
nonobviousness requirement is not fulfilled by the mere nanoscale “miniaturization” of
already-patented products.58 In re Rose involved claims to an apparatus and methods of
packaging, handling, and storing lumber where the claimed invention related merely to a
difference in size from that in the prior art.59 Analogizing to this case, merely scaling
down to the nanoscale would conflict with In re Rose.
¶20
However, where a patent application also provides a novel use and utility (and
fulfills all other patentability requirements) in addition to identifying and claiming a
difference in scale, it would be eligible for patent protection. Of course, this also depends
50

KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 399 (2007).
Id. at 400.
52
383 U.S. 1 (1966).
53
KSR, 550 U.S. at 417. The Court stated:
Often, it will be necessary for a court to look to interrelated teachings of multiple patents; the
effects of demands known to the design community or present in the marketplace; and the
background knowledge possessed by a person having ordinary skill in the art, all in order to
determine whether there was an apparent reason to combine the known elements in the
fashion claimed by the patent at issue. To facilitate review, this analysis should be made
explicit. As our precedents make clear, however, the analysis need not seek out precise
teachings directed to the specific subject matter of the challenged claim, for a court can take
account of the inferences and creative steps that a person of ordinary skill in the art would
employ.
Id. at 418 (citations omitted).
54
Id. at 418, 419.
55
For a discussion of the case’s relevance to nanotechnology, see Matthew J. Dowd et al., KSR
International Co. v. Teleflex Inc.: Another Small Issue for Nanotechnology?, 4 NANOTECHNOLOGY L. &
BUS. 293 (2007).
56
In re Rose, 220 F.2d 459 (C.C.P.A. 1955).
57
Id.
58
R. Scott Roe, Note, Nanotechnology: When Making Something Smaller is Nonobvious, 12 B.U. J. SCI. &
TECH. L. 127, 130 (2006) (citing Vivek Koppikar et al., Current Trends in Nanotech Patents: A View from
Inside the Patent Office, 1 NANOTECH. L. & BUS. 24, 28 (2004)).
59
In re Rose, 220 F.2d at 463 (“Appellant argues that this claim recites that the package is of appreciable
size and weight so as to require handling by a lift truck whereas [the prior art references’] packages can be
lifted by hand. We do not feel that this limitation is patentably significant since it at most relates to the size
of the article under consideration which is not ordinarily a matter of invention.”).
51
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on the scope of the claims present in prior art patents and whether a size range that
covered the nanoscale was specifically claimed in the prior art patent that covered the
nanotechnology invention for which a patent is sought.60 The USPTO has indicated that
patent applicants would be more likely to avoid rejection on obviousness grounds if they
affirmatively provide both a statement that the prior art did not recognize that the
reduction of the disclosed invention to nanoparticle size would have specific benefits and
recite a standard deviation from average particle size.61
¶21
Case law also establishes that a product claim is not obvious unless the process for
making that product is also obvious.62 This relates to the level of ordinary skill in the art,
as measured from the date of the invention. Courts have examined this in the context of
crystalline drug forms.63 For nanotechnology, inventors should explicitly set forth that
the methods for making the nano-sized invention were not obvious because the methods
to scale it either top-down or bottom-up did not exist at the time of the prior art.64
¶22
Anticipation is another facet of obviousness that has been discussed in the context
of nanotechnology. A patent claim is deemed “anticipated” by the prior art “if each and
every limitation is found either expressly or inherently in a single prior art reference.”65
Despite a finding of novelty based on the newfound properties grounded in changes in
size, patent claims may face “inherency” rejections where the claimed invention focuses
on the inherent properties at the nanoscale.66 The doctrine of inherency allows the
examiner to locate similar art and argue that the claimed property is inherently or
necessarily possessed in that prior art because it “necessarily flows from the teachings of
the applied prior art.”67 This strong reliance on nanoscale properties may complicate the
patent examination process, as searching prior art for size and property limitations is not
an easy task where inventions span numerous scientific fields. As a result, many
examiners are inclined to reject the application for inherency.68 For example, a
substantially identical structure or composition may establish a prima facie case of
obviousness, even if the claimed nanotechnology characteristic is not disclosed or
claimed in the prior art.69 However, as discussed in Part III, the USPTO nanotechnology
classification aims to ameliorate some of these problems.

60

Part II-B, infra, discusses this in terms of literal infringement and the reverse doctrine of equivalents.
USPTO Holds Second Nanotechnology Customer Partnership Meeting, USPTO CONNECTION (Moazzam
Latimer LLP, McLean, Va.), May 2004, at 3, http://www.moazzamlaw.com/dev/Vol1-Issue1.pdf
[hereinafter Second Nanotechnology Meeting].
62
Jeremy M. Stipkala, Overcoming Obviousness When Patenting Nanotechnology Inventions, 23 NATURE
BIOTECHNOLOGY 677, 677 (2005).
63
Id. (citing In re Irani, 427 F.2d 806 (C.C.P.A. 1970)).
64
Id. at 678.
65
Celeritas Techs., Ltd. v. Rockwell Int’l Corp., 150 F.3d 1354, 1361 (Fed. Cir. 1998).
66
Nikolas J. Uhlir, Note, Throwing a Wrench in the System: Size-Dependent Properties, Inherency, and
Nanotech Patent Applications, 16 FED. CIR. B.J. 327, 342 (2007).
67
Id. at 343–44.
68
Id. at 339–41.
69
Id.
61

178

Vol. 10:3]

Jordan Paradise

5. Specification
¶23

In addition to showing the utility, novelty, and nonobviousness of the claimed
invention, the applicant must also include a specification.70 This specification must
include a written description that provides the manner and process of making and using
the invention in such concise, exact terms as to “enable any person skilled in the art” to
make and use it.71 Pursuant to this section, the applicant also must set forth the best mode
of carrying out the invention and must sufficiently disclose the invention.72 As the
second paragraph of § 112 mandates, the specification section must conclude with “one
or more claims particularly pointing out and distinctly claiming the subject matter” of the
invention.73 This two-paragraph section offers the public the general knowledge included
in the patent in return for the exclusive patent rights to the invention being awarded to the
inventor.74 Patent examiners use the specification to interpret the scope of the claims and
relationship to the prior art.
¶24
The Federal Circuit recently visited the scope of the written description
requirement in Ariad Pharmaceuticals, Inc., v. Eli Lilly & Co.75 Ariad and its research
partners discovered the activation mechanisms of the NF-kB protein in human cells in
response to certain diseases such as AIDS and various cancers, and they identified how
the protein subsequently binds to other cells in the human body and causes the cells to
produce proteins that fight infections.76 The proteins produced by NF-kB are harmful
when produced in such excess.77 Ariad filed a patent for methods to reduce binding of
NF-kB to limit the negative impacts of excess protein production.78 However, when it
submitted its patent application, Ariad had not finalized the listed techniques it claimed
could effectively reduce NF-kB binding. On review, the Federal Circuit examined the
state of jurisprudence regarding written description.
¶25
The court addressed two primary issues in Ariad: (1) whether § 112 contains a
written description requirement separate from the enablement requirement; and (2) if so,
the scope of that written description requirement.79 The court provided a lengthy analysis
70

35 U.S.C. § 112 (2006) (“The specification shall contain a written description of the invention, and of the
manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any
person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the
same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. The
specification shall conclude with one or more claims particularly pointing out and distinctly claiming the
subject matter which the applicant regards as his invention.”).
71
Id.
72
Id. The best mode requirement pertains to the best mode as contemplated by the inventor at the time of
invention.
73
Id.
74
See Rebecca S. Eisenberg, Patents and the Progress of Science: Exclusive Rights and Experimental Use,
56 U. CHI. L. REV. 1017, 1022 (1989).
75
598 F.3d 1336 (Fed. Cir. 2010). For a thoughtful analysis of the case, see Joseph Jakas, Comment,
Encouraging Further Innovation: Ariad v. Eli Lilly and the Written Description Requirement, SETON HALL
L. REV. (forthcoming 2012).
76
Ariad Pharm., Inc. v. Eli Lilly & Co., 560 F.3d 1366, 1369–70 (Fed. Cir. 2009).
77
Ariad Pharm., 598 F.3d at 1340.
78
Id. at 1355. These techniques included manipulating NF-kB inhibitors, using an NF-kB molecule that
did not have the ability to produce the harmful proteins, or using decoy molecules to bind to NF-kB binding
sites. Id. at 1356.
79
Id. at 1342.
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of the history and interpretation of § 112, looking to the statute and relevant court
precedent. The Federal Circuit determined that the two requirements were, indeed,
separate and that the written description requirement should be applied to original
claims.80 The court further held that an inventor must specifically show “possession [of
the claimed invention] as shown in the disclosure” upon filing of the patent application.81
Thus, an inventor would not satisfy the requirement by describing a broad method and
listing a few ways to accomplish that method. Without a more detailed description, the
inventor fails to possess the full scope of the claimed invention.
¶26
Although how lower courts will interpret and apply this decision remains unclear
and somewhat controversial, the Federal Circuit’s decision in Ariad may have an impact
on nanotechnology patents that claim a broad range of sizes. After Ariad, an inventor
must show in the disclosure of the invention that she was able to produce the size within
the range being claimed. To accomplish this, the inventor should disclose separate
species within the claimed range rather than general description of a broad category. The
inventor should also be specific about the effects of the invention, linking the disclosed
structure and size to the desired function of the claimed invention. The core failure of the
Ariad patent is that it merely predicted how certain claimed techniques would have the
desired effects of reducing binding before actually achieving those effects as a result of
the research. Nanotechnology inventions could have similar issues with the possession
requirement if they disclose unfinished (yet informative) research findings to claim an
invention not yet completed.
B. Critiques of Nanotechnology Patenting
¶27

Academics82 and practitioners83 alike have written on the topic of nanopatenting,
focusing much of their discussion on the scope of claims and the approach to claim
80

The court parsed out the statute as: the specification must contain (1) a written description of the
invention and (2) a written description “of the manner and process of making and using [the invention] in
such full, clear, concise, and exact terms as to enable any person skilled in the art . . . to make and use the
same.” Id. at 1344.
81
Id. at 1351 (internal quotation marks omitted).
82
See, e.g., Indrani Barpujari, The Patent Regime and Nanotechnology: Issues and Challenges, 15 J.
INTELL. PROP. RTS. 206 (2010); Diana M. Bowman & Graeme A. Hodge, A Small Matter of Regulation: An
International Review of Nanotechnology Regulation, 8 COLUM. SCI. & TECH. L. REV. 1 (2007); K. Eric
Drexler & Jason Wejnert, Nanotechnology and Policy, 45 JURIMETRICS J. 1 (2004); Frederick A. Fiedler &
Glenn H. Reynolds, Legal Problems of Nanotechnology: An Overview, 3 S. CAL. INTERDISC. L.J. 593
(1994); Ernest J. Getto et al., Nanotechnology: Will Tiny Particles Create Large Legal Issues?, SCITECH
LAW., Summer 2009, at 6, 6; Dennis S. Karjala, Protecting Innovation in Computer Software,
Biotechnology, and Nanotechnology, 16 VA. J.L. & TECH. 42 (2011); Mark A. Lemley, Patenting
Nanotechnology, 58 STAN. L. REV. 601 (2005); Thomas M. Mackey, Nanobiotechnology, Synthetic
Biology, and RNAi: Patent Portfolios for Maximal Near-Term Commercialization and Commons for
Maximal Long-Term Medical Gain, 13 MARQ. INTELL. PROP. L. REV. 123 (2009); Glenn Harlan Reynolds,
Nanotechnology and Regulatory Policy: Three Futures, 17 HARV. J.L. & TECH. 179 (2003); Douglas J.
Sylvester & Diana M. Bowman, Navigating the Patent Landscape for Nanotechnology: English Garden or
Tangled Grounds?, in BIOMEDICAL NANOTECHNOLOGY: METHODS AND PROTOCOLS 359 (Sarah J. Hurst
ed., 2011); Georgios I. Zekos, Patenting Abstract Ideas in Nanotechnology, 9 J. WORLD INTELL. PROP. 113
(2006).
83
See, e.g., Laurie A. Axford, Patent Drafting Considerations for Nanotechnology Inventions, 3
NANOTECHNOLOGY L. & BUS. 305 (2006); Raj Bawa, Nanotechnology Patenting in the US, 1
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drafting.84 The claims are critical during review by examiners to determine scope and
whether an invention has an adequate written description. Similar to arguments raised
regarding the emergence of biotechnology and genetic technologies at the end of the last
century and the beginning of the twenty-first century,85 some contend that the
proliferation of nanotechnology patents may create a patent thicket due to overlapping
claims.86
¶28
Due to the nature of broad claim drafting, nanotechnology-related patents are likely
to literally infringe traditional product patents with broad claims and no reference to
scale. However, many scholars posit that the reverse doctrine of equivalents may
preclude a finding of literal infringement where the claimed invention is sufficiently
different from the previously patented product, despite the fact that the accused claimed
invention literally infringes the accuser’s patent claims.87 The reverse doctrine of
equivalents was espoused by the Supreme Court in Graver Tank & Manufacturing Co. v.
Linde Air Products Co.:
[W]here a device is so far changed in principle from a patented article that it
performs the same or a similar function in a substantially different way, but
nevertheless falls within the literal words of the claim, the doctrine of equivalents
may be used to restrict the claim and defeat the patentee’s action for
infringement.88

Two requirements must be satisfied for the reverse doctrine of equivalents to apply: the
accused product must literally infringe the accuser’s patent claims while also being
“sufficiently different” from the patented product.89
¶29
Both Congress and the Federal Circuit have supported the basic principles of the
reverse doctrine of equivalents set out by the Supreme Court. In enacting § 112 in 1952,

NANOTECHNOLOGY L. & BUS. 31 (2004); Dowd et al., supra note 55; Drew Harris et al., Strategies for
Resolving Patent Disputes Over Nanoparticle Drug Delivery Systems, 1 NANOTECHNOLOGY L. & BUS. 372
(2004); Koppikar et al., supra note 58; John Josef Molenda, The Importance of Defining Novel Terms in
Patenting Nanotechnology Inventions, 1 NANOTECHNOLOGY L. & BUS. 174 (2004); Sean O’Neill et al.,
Broad Claiming in Nanotechnology Patents: Is Litigation Inevitable?, 4 NANOTECHNOLOGY L. & BUS. 29
(2007).
84
See Nanotechnology Gold Rush Yields Crowded, Entangled Patents, PRNEWSWIRE (Apr. 21, 2005),
http://www.prnewswire.com/news-releases/nanotechnology-gold-rush-yields-crowded-entangled-patents54373177.html. For example, Stephen B. Maebius, chair of the Nanotechnology Industry Team at Foley &
Lardner LLP, advised companies filing nanotech patents to draft claims of intermediate scope rather than
broad claims in response to court determinations in a number of biotechnology patents that held such broad
claims invalid. Id.
85
See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anticommons in
Biomedical Research, 280 SCIENCE 698, 698 (1998) (citing Garrett Hardin, The Tragedy of the Commons,
162 SCIENCE 1243 (1968)).
86
See, e.g., Lemley, supra note 82; Sylvester & Bowman, supra note 82.
87
See, e.g., Lemley, supra note 82; Terry K. Tullis, Application of the Government License Defense to
Federally Funded Nanotechnology Research: The Case for a Limited Patent Compulsory Licensing
Regime, 53 UCLA L. REV. 279 (2005); Andrew Wasson, Protecting the Next Small Thing: Nanotechnology
and the Reverse Doctrine of Equivalents, 2004 DUKE L. & TECH. REV. 0010, available at
http://www.law.duke.edu/journals/dltr/articles/2004dltr0010.
88
Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605, 608–09 (1950).
89
Texas Instruments, Inc. v. U.S. Int’l Trade Comm’n, 846 F.2d 1369, 1371 (Fed. Cir. 1988).
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Congress imposed “requirements for the written description, enablement, definiteness,
and means-plus-function claims that are co-extensive with the broadest possible reach of
the reverse doctrine of equivalents.”90 The Federal Circuit said that the reverse doctrine
of equivalents and § 112 “spring from the same roots and very often take account of the
same factors and considerations”91 and the Supreme Court said that § 112 is “an
application of the doctrine of equivalents in a restrictive role.”92 Given this view that the
1952 amendments codified the reverse doctrine of equivalents, the Federal Circuit has
never relied upon the reverse doctrine of equivalents to affirm a decision of
noninfringement independently of a § 112 analysis.93 Some predict that, although the
reverse doctrine of equivalents has existed only in theory for the last sixty years, it may
be a successful defense for nanotechnology patent holders against claims of literal
infringement.94 Unique properties at the nanoscale may perform a similar function as
chemicals, materials, or processes at the micro scale or macro scale, but operate in a
substantially different manner. For example, nanocrystals diffuse at different rates given
extremely small changes in size. Recent breast cancer research reports that the time for a
100 nm nanocrystal particle to reach tumor cells was two and a half times that of 20 nm
particles (389 minutes as compared to 158 minutes).95 One can assume that much larger
particles, in the range of traditional pharmaceuticals, take much longer to reach a target
site because of biological interactions.
This has enormous implications for
pharmaceutical development and pharmacokinetics, in that the purpose (i.e., drug
delivery) remains the same, yet the rate of diffusion and biological and pharmacological
interactions may differ dramatically.
¶30
Many of these projections remain untested because patent litigation targeted to
nanotechnology has been limited thus far. However, future cases are likely to attack
issues of patentability under § 101 in the context of genetic sequence patents, as well as
the specific application of the core substantive requirements. The USPTO, the agency
actively reviewing and issuing nanotechnology patents, is presently tackling many of
these questions. If genetics are a litmus test for emerging medical technologies, then
developments and inventions in nanotechnology (and nanopharmaceuticals specifically)
will soon be appearing in court dockets. Part III provides an overview of the USPTO’s
efforts to gather information and classify inventions that utilize nanotechnology.

90

Tate Access Floors, Inc. v. Interface Architectural Res., Inc., 279 F.3d 1357, 1368 (Fed. Cir. 2002).
However, their application differs as to the timing of the inquiry. Whereas a § 112 analysis is made during
examination of the patent application or during a court’s determination of patentability, the reverse doctrine
of equivalents serves as a defense to a claim of literal infringement where a court’s inquiry is focused on
the alleged infringing product’s characteristics.
91
Texas Instruments, 846 F.2d at 1372 (Davis, J., concurring in part).
92
Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 28 (1997).
93
Tate Access Floors, 279 F.3d at 1368.
94
See, e.g., M. Veronica Mullally & David R. Winn, Patenting Nanotechnology: A Unique Challenge to IP
Bar, N.Y. L.J., July 6, 2004, at t2.
95
Masaaki Kawai et al., Dynamics of Different-Sized Solid-State Nanocrystals as Tracers for a DrugDelivery System in the Interstitium of a Human Tumor Xenograft, 11 BREAST CANCER RES. R43 (2009),
http://www.biomedcentral.com/content/pdf/bcr2330.pdf.
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III. THE USPTO NANOCLASSIFICATION
¶31

The term nanotechnology encompasses an array of technologies at the nanoscale,
where “nanoscale” refers to measurements less than 100 nm (i.e., 10-9 m; one billionth of
a meter). The NNI’s definition of nanotechnology involves three inter-related (and
inseparable) aspects:
[(1)] Research and technology development at the atomic, molecular or
macromolecular levels, in the length scale of approximately 1–100 nanometers,
[(2)] Creation and use of structures, devices and systems that have novel
properties and functions because of their small and/or intermediate sizes, and
[(3)] Ability to be controlled or manipulated on the atomic scale.96

To earn the term nanotechnology, a particle or material must possess unique physical,
chemical, or biological properties at the nanoscale that make that particle or material
function in a manner that can be harnessed and controlled to utilize those unique
properties. As discussed above, the USPTO has adopted a variation of the NNI definition
for nanotechnology, keying in on the 1 to 100 nm range.97 Nanobiotechnology merges
nanotechnology and biotechnology and is described as “a field that applies the nanoscale
principles and techniques to understand and transform biosystems . . . and which uses
biological principles and materials to create new devices and systems integrated from the
nanoscale.”98 Nanomedicine is an important facet of research and development, which,
according to the National Institutes of Health, “refers to highly specific medical
intervention at the molecular scale for curing disease or repairing damaged tissues, such
as bone, muscle, or nerve.”99 There is widespread research activity in biomolecule and
biomimetic devices, biosensors, molecular motors, biomolecular fabrics, engineered
enzymes and proteins, and drug discovery and delivery.100 The pharmaceutical and
medical device industries, two of the most patent-motivated industries, are at the
forefront of nanotechnology research and development.
¶32
One source reports that the USPTO began issuing nanotechnology-related patents
as early as 1976.101 However, it was not until the infusion of federal research funding for
nanotechnology research and development that the unifying term nanotechnology made
96

ENVTL. PROT. AGENCY, NANOTECHNOLOGY: AN EPA RESEARCH PERSPECTIVE, FACTSHEET 1 (2007),
available at http://epa.gov/ncer/nano/factsheet/nanofactsheetjune07.pdf.
97
See supra pp. 3–4.
98
Mihail C. Roco, Nanotechnology: Convergence with Modern Biology and Medicine, 14 CURRENT
OPINION IN BIOTECHNOLOGY 337, 337 (2003).
99
Nanomedicine Overview, NAT’L INST. OF HEALTH COMMON FUND,
http://commonfund.nih.gov/nanomedicine/overview.aspx (last updated Jan. 1, 2011).
100
Alan L. Porter et al., Refining Search Terms for Nanotechnology, 10 J. NANOPARTICLE RES. 715, 718
(2008).
101
Tyson Winarski, Esq. & Elizabeth Stoker-Townsend, Nanotechnology Thriving on Patents, INTELL.
PROP. TODAY, Apr. 2005, at 26 (citing the National Science Foundation). However, the first patent within
the USPTO patent classification system was filed in September 1975 and issued in August 1978. Injectable
Compositions, Nanoparticles Useful Therein, & Process of Mfg. Same, U.S. Patent No. 4,107,288 (filed
Sept. 9, 1975).
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its way into the scientific and technical literature and into patent applications for
inventions. In response to a surge of nanotechnology inventions, the USPTO embarked
on a multi-phase project to systematically identify nanotechnology-related patents, patent
applications, and research publications to ultimately develop a method of classification to
capture the breadth of nanotechnology.102 The USPTO’s goals in developing a
nanotechnology classification system were to construct a uniform framework to
standardize the terminology, create an effective system for disclosure and crossreferencing, assist inventors and examiners in identifying and reviewing relevant prior
art, and decrease inadvertent patent infringement.
A. Development of the “977” Class
¶33

The USPTO initiated the 977 classification project in November 2001, recognizing
that patent examiners assessing nanotechnology patent applications were increasingly
confronted with challenges relating to their level and type of training and the
multidisciplinary features of nanotechnology. These challenges included a lack of
familiarity with the underlying science and technologies, the utilization of complex and
often new terminology, and the expanse of the scientific literature. These difficulties
increased the risk that examiners were not equipped to assess the scope of the invention
and previous inventions and increased the risk that relevant publications would be
overlooked during examination.103 The USPTO recognized that the broad range of
technological specialty areas and prior art reflected in the applications increased the
likelihood that separate patent examiners would contemporaneously issue overlapping or
even conflicting patents.104
¶34
Cognizant of these challenges facing examiners, the USPTO initiated the
nanotechnology classification project. This multi-phase project proceeded incrementally
in three core phases. The first was defining and setting the scope of nanotechnology for
USPTO purposes; the second was creation of a cross-reference digest; and the third was
the development of the 977 classification system. To develop a classification of
nanotechnology patents and to cross-reference the patents and supporting documents, the
USPTO established a definition for purposes of “searching for, identifying, and
classifying documents” related to nanotechnology.105 The USPTO arrived at a definition
of nanostructure “to mean an atomic, molecular, or macromolecular structure that: (a)
[h]as at least one physical dimension of approximately 1–100 nanometers; and (b)
[p]ossesses a special property, provides a special function, or produces a special effect

102

35 U.S.C. § 8 provides authority to the USPTO to classify patents. It reads: “The Director may revise
and maintain the classification by subject matter of United States letters patent, and such other patents and
printed publications as may be necessary or practicable, for the purpose of determining with readiness and
accuracy the novelty of inventions for which applications for patents are filed.” Id.
103
See Barnaby J. Feder, Tiny Ideas Coming of Age, N.Y. TIMES, Oct. 24, 2004, at WK12.
104
See, e.g., EROSION, TECH., & CONCENTRATION GRP., NANOTECH’S “SECOND NATURE” PATENTS:
IMPLICATIONS FOR THE GLOBAL SOUTH 8 (2005),
http://etcgroup.org/upload/publication/54/02/com8788specialpnanomar-jun05eng.pdf [hereinafter
NANOTECH’S “SECOND NATURE” PATENTS].
105
Vance McCarthy, USPTO Poised to Ring in a New Era of Simplified Search and Better Visibility for
Nano Patents, NANO SCI. & TECH. INST. (Dec. 20, 2005), http://www.nsti.org/news/item.html?id=35.
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that is uniquely attributable to the structure’s nanoscale physical size.”106 The USPTO
then established five categories of inventions involving nanotechnology:
(1)
nanostructures and chemical compositions; (2) devices that include at least one
nanostructure; (3) mathematical algorithms; (4) methods or apparatuses for making,
detecting, analyzing or treating nanostructure; and (5) specified uses of nanostructures.107
¶35
The agency next organized a task force consisting of twenty-five internal patent
professionals from USPTO technology centers and the classification office to develop a
list of nanotechnology-related terms used by inventors that would assist in the
identification of nanotechnology publications within the existing patent database. The
task force developed 150 search terms to be employed to sketch out trends and concepts
emerging from the patented inventions relating to nanotechnology. To garner input from
the larger community of consumers of nanoproducts, the USPTO also invited the public
to a series of Nanotech Partnership Meetings108 through a Nanotechnology Customer
Partnership initiative. The initiative was envisioned by the USPTO as “a forum to share
ideas, experiences, and insights between individual users and the USPTO.”109 To further
inform the process, the USPTO also initiated a trilateral discussion on the topic of
effective and consistent international review of nanotechnology applications and
development of classes and subclasses for nanotechnology inventions with the European
Patent Office and Japanese Patent Office.110
¶36
As a result of these efforts, the USPTO in August of 2004 established a
nanotechnology cross-reference digest—designated Class 977, Digest 1. This crossreference digest operated by gathering all nanotechnology publications in a single place,
replacing the inefficient keyword searches of prior art in multiple scientific fields by
examiners.111 The Office of the Commissioner of Patents provided that the new 977
cross-reference digest would (1) “[f]acilitate the searching of prior art related to
Nanotechnology”; (2) “[f]unction as a collection of issued U.S. patents and published
pre-grant patent applications relating to Nanotechnology across the technology centers”;
and (3) “[a]ssist in the development of an expanded, more comprehensive,
nanotechnology cross-reference art collection classification schedule.”112
¶37
The important efficiency outcome of the cross-reference digest was to weed out
prior art that was not actually developed by nanotechnology or did not actually contain
nano-sized materials. For a variety of reasons, including the massive federal funding
initiative supporting nanotechnology research and development as well as
misunderstandings about nanotechnology, many inventors, scientists, and companies
(often inaccurately) describe their research, inventions, or resulting products as involving
106

U.S. PATENT & TRADEMARK OFFICE, CLASSIFICATION DEFINITIONS: CLASS 977, NANOTECHNOLOGY 1
(2010) [hereinafter CLASS 977 DEFINITIONS], available at
http://www.uspto.gov/web/patents/classification/uspc977/defs977.pdf.
107
Id.
108
McCarthy, supra note 105.
109
Nanotechnology Customer Partnership Meeting, U.S. PAT. & TRADEMARK OFF.,
http://www.uspto.gov/patents/init_events/nanotech.jsp (last updated July 4, 2009).
110
Second Nanotechnology Meeting, supra note 61.
111
NANOTECH’S “SECOND NATURE” PATENTS, supra note 104, at 8; McCarthy, supra note 105.
112
Memorandum from the Office of the Comm’r for Patents to Patent Prof’l Emps., Nanotechnology
Digest and Forthcoming Nanotechnology Cross-Reference Art Collection (XRAC)—Class 977 (Aug. 25,
2004), http://www.uspto.gov/web/offices/pac/dapp/opla/documents/nanotechdig.pdf.
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or containing nanotechnology. For example, a keyword search of the prefix nano in the
USPTO patent database returns tens of thousands of results where the majority of these
patents are not technically nanotechnology as defined and classified by Class 977, Digest
1. Creating a nano-specific definition and class requirements has aided the USPTO in
identifying and assessing prior art by eliminating irrelevant prior art from the start.
However, the classification is also constrained by the USPTO’s definition of
nanotechnology.113
¶38
The USPTO next converted the single digest to a nanotechnology classification
schedule with 263 cross-reference art collection subclasses,114 facilitating the routing of
patent applications to examiners with particular expertise. The USPTO based these
classes on international patent classes available, as well as prior experience. In
November 2005, the USPTO Classification Order 1850 officially abolished Class 977,
Digest 1 and established the Class 977 and the cross-reference art collection Subclasses
700 through 963.115 Each contained subclass definitions and a search note.116
¶39
While there is no centralized nanotechnology art unit within the USPTO centers,
the 977 Class assists in locating applications and distributing among art units.117 The
lack of a nanotechnology art unit means that, to date, the USPTO has not assigned a
group of “nano” examiners because of the diversity of nanotechnology inventions. When
an application is submitted to the USPTO, it is distributed to one or more of the existing
art units and linked subclasses such as “chemistry: molecular biology and microbiology”
(Class 435) or “drug, bio-affecting and body treating compositions” (Class 424) based on
the patent claims, and then filtered to the 977 classification as a cross-reference tool. In
tandem with creation of the 977 classification, the USPTO has partnered with outside
professionals and experts to train and educate patent examiners on nanotechnology
terminology and concepts.118
B. Nanopharmaceutical Subclassifications
¶40

The 977 classification is comprised of 263 subclassifications: 700 through 963.
Subclassifications 700 to 838 encompass various forms of a “nanostructure.”119
Subclassification 839 is reserved for mathematical algorithms “specifically adapted for

113

See discussion supra notes 106–107 and accompanying text.
Charles R. Eloshway, Nanotechnology-Related Issues at the United States Patent and Trademark Office,
COMMUNITY RES. & DEV. INFO. SERVICE 5 (Dec. 2006),
ftp://ftp.cordis.europa.eu/pub/nanotechnology/docs/iprworkshop_eloshway_en.pdf.
115
David J. Robeson, Nanotechnology and the USPTO, NAT’L ASS’N PAT. PRAC. 3 (2006),
http://www.napp.org/disclosure/linked_files/Nanotechnology%20and%20the%20USPTO_05.01.2006.pdf.
116
CLASS 977 DEFINITIONS, supra note 106.
117
Where Science and Law Meet: Nanotechnology and Intellectual Property Issues, NAT’L CANCER INST. 3
(Oct. 2006), http://nano.cancer.gov/action/news/featurestories/monthly_feature_2006_oct.pdf [hereinafter
Where Science and Law Meet].
118
Feder, supra note 103; Patent Office Struggles to Stay Ahead of Nanotech Industry, ELECTRO IQ (Apr.
20, 2004), http://www.electroiq.com/index/display/nanotech-article-display/269406/articles/smalltimes/legal/2004/04/patent-office-struggles-to-stay-ahead-of-nanotech-industry.html.
119
U.S. PATENT & TRADEMARK OFFICE, CROSS-REFERENCE ART COLLECTIONS: CLASS 977
NANOTECHNOLOGY 1–3 (2010), available at
http://www.uspto.gov/web/patents/classification/uspc977/sched977.pdf [hereinafter CLASS 977 SCHEDULE].
114
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modeling configurations or properties of [a] nanostructure”;120 subclassifications 840 to
901 encompass “manufacture, treatment, or detection of [a] nanostructure”;121
subclassifications 902 to 962 encompass “specified use of [a] nanostructure”;122 and
subclassification 963 is reserved for miscellaneous.123
¶41
The subclassifications within the 977 class most relevant to nanomedicine and
pharmaceutical development are those that fall into subclassifications 904 through 926.
These are specified uses of nanostructure for “medical, immunological, body treatment or
diagnosis,” divided into areas such as “drug delivery” (977/906), “mechanical repair
performed/surgical” (977/908), “therapeutic or pharmaceutical composition” (977/915),
“vaccine” (977/917), and “topical chemical” (977/926).124 A particular patent will first
list its primary classifications and subclassifications and then list the 977 cross-reference
classifications and subclassifications. As of May 31, 2011, the 977/904 through 977/926
classifications consist of a total of 896 patents, many of which are listed in multiple
subclassifications based on the substance of their claims.125

120

Id. at 3.
Id. at 4.
122
Id.
123
Id. at 5.
124
See infra Figure 1.
125
This count was retrieved using a specific methodology to eliminate duplicate patents listed in multiple
sub-classifications. USPTO Patent Full-Text and Image Database, supra note 5 (search “Query” for
“ccl/977/904 or ccl/977/905 or ccl/977/906 or ccl/977/907 or ccl/977/908 or ccl/977/909 or ccl/977/91$ or
ccl/977/920 or ccl/977/921 or ccl/977/922 or ccl/977/923 or ccl/977/924 or ccl/977/925 or ccl/977/926”).
121
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FIGURE 1. USPTO NANOTECHNOLOGY SUBCLASSIFICATIONS 977/902 THROUGH
977/926126
977/902: Specified Use of Nanostructure
977/903: For conversion, containment, or destruction of hazardous material
977/904: For medical, immunological, body treatment, or diagnosis
977/905: Specifically adapted for travel through blood circulatory system
977/906: Drug delivery
977/907: Liposome
977/908: Mechanical repair performed/surgical
977/909: Obstruction removal
977/910: Strengthening cell or tissue
977/911: Cancer cell destruction
977/912: Cancer cell repair
977/913: Stem cell therapy implantation
977/914: Protein engineering
977/915: Therapeutic or pharmaceutical composition
977/916: Gene therapy
977/917: Vaccine
977/918: Immunological
977/919: Dental
977/920: Detection of biochemical
977/921: Of toxic chemical
977/922: Of explosive material
977/923: Cell culture
977/924: Using nanostructure as support of DNA analysis
977/925: Bioelectrical
977/926: Topical chemical (e.g., cosmetic or sunscreen, etc.)

¶42

Patents for various FDA-approved and marketed pharmaceutical products have
been classified in the 977 cross-reference system. For example, within the Orange
Book127 listing for Depocyt, an FDA-approved nanoparticle formulation of cytarbine for
treatment of lymphomatous meningitis, the patent and exclusivity references include U.S.
Patent No. 5,455,044 (method for treating neurological disorders).128 In the patent itself,
the primary classification is 424/450 (drug, bio-affecting, and body-treating
compositions; preparations characterized by physical form; liposomes), followed by
977/907 (nanotechnology; specified use of nanostructure for medical, immunological,
body treatment or diagnosis; specifically adapted for travel through blood circulatory
system; liposome), 977/911 (nanotechnology; specified use of nanostructure for medical,
immunological, body treatment or diagnosis; mechanical repair performed; surgical;
cancer cell destruction), and 977/915 (nanotechnology; specified use of nanostructure for
medical, immunological body treatment, or diagnosis; therapeutic or pharmaceutical
composition). Similarly, the Orange Book listing for Estrasorb, an FDA-approved
micellar nanoparticle estrogen delivery system for topical treatment of menopausal hot
flashes, lists U.S. Patent No. 5,629,021 (micellar nanoparticles) within the patent and
126

CLASS 977 SCHEDULE, supra note 119.
The Orange Book is a publication of the Food and Drug Administration that lists patent and exclusivity
information for pioneer and generic drugs. The searchable electronic version is available at Orange Book:
Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. FOOD & DRUG ADMIN.,
http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm (last updated Oct. 28, 2011).
128
Method for Treating Neurological Disorders, U.S. Patent No. 5,455,044 (filed May 14, 1993).
127
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exclusivity references.129 This patent’s primary classification is 424/489 (drug, bioaffecting and body treating compositions; preparations characterized by physical form;
particulate form), followed by 977/915 (nanotechnology; specified use of nanostructure
for medical, immunological, body treatment or diagnosis; therapeutic or pharmaceutical
composition) and 977/926 (nanotechnology; specified use of nanostructure for medical,
immunological body treatment or diagnosis; topical chemical).
¶43
However, the underlying patents for many pharmaceutical products utilizing
nanotechnology that have been approved by the FDA and are currently on the market
have not been classified by the USPTO as nanotechnology.130 As discussed below, there
may be a variety of reasons for this, including the particular claim drafting, date of patent
application, or other special circumstances relating to product development and
commercialization.
For example, many of the FDA-approved drugs utilizing
nanotechnology were approved well before the USPTO implemented the 977
classification system.131
¶44
As the Appendix illuminates, the development of such a nanotechnology
classification system, while proactive on the part of the USPTO, suffers from a number of
limitations. The first major limitation is the USPTO’s cut-off at 100 nm or less particle
size. As described below, the first litigation involving an FDA-approved nanodrug was
based on a preexisting patent that had not been classified by the USPTO in their
nanotechnology classification because the claims regarding particle size exceeded the 100
nm ceiling (and the patent application was filed well before 2004). In fact, Abraxane,
one of the first marketed nanodrugs and the subsequent product at issue in the litigation
described in Part IV, has a 130 nm mean particle size;132 the claim drafting moved that
into the 977 classification based on the use of the phrase “less than about 200 nm”
coupled with examples provided within the patent specification within the 50–220 nm
range, which begins below 100 nm.133 Because of broad claiming, many patents that
have been awarded may be inaccurately excluded from the nanotechnology classification.
In reality, nanomedicine products resulting from such patents could be deemed nano for
FDA purposes (the Center for Drug Evaluation and Research within the FDA defines

129

Micellar Nanoparticles, U.S. Patent No. 5,629,021 (filed Jan. 31, 1995).
These products were identified using a two-pronged search methodology: a search of the relevant
scientific literature reporting on research and development in nanopharmaceuticals and the FDA’s website
providing information on FDA-approved drugs, Drugs@FDA Database, U.S. FOOD & DRUG ADMIN.,
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (last visited Dec. 20, 2011). Where a
product was identified in the scientific literature as a nanopharmaceutical, the FDA database was used to
retrieve that product’s approval information. Searches were conducted from January 2011 through May
2011. The Appendix references all scientific sources.
131
The Appendix provides information both from the scientific literature and the FDA on FDA-approved
nanotechnology pharmaceutical products. Of the twenty-six products identified in the Appendix, only three
of them have patents listed in the Orange Book that have been classified by the USPTO as qualifying for
the 977 nanotechnology classification (i.e., Abraxane, DepoCyt, and Estrasorb).
132
See ABRAXIS BIOSCIENCE, ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING BRIEFING PACKAGE:
ABRAXANE (Aug. 4, 2006), http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4235B2-0101AbraxisBioscience-background.pdf.
133
Compositions & Methods of Delivery of Pharmacological Agents, U.S. Patent No. 7,820,788 B2 col. 38
l. 22 (filed Oct. 26, 2006).
130
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nanoscale material as having a particle size of less than 1,000 nm)134 and not for USPTO
purposes (defining nano as having a particle size of 100 nm or less). Other drug products
may deviate from the 100 nm ceiling depending on the size of the actual nanodrug
product compared to the total size of the particle containing the drug product and any
encapsulating material or adjuvant.
¶45
The second limitation is that the USPTO began the classification project in 2004,
without installing a uniform mechanism to retroactively reclassify existing patents into
the new 977 classification system. Retroactively classifying already-issued patents into
the new classification system was encouraged, though not required: “While every effort
has been made to make the subclasses as complete as possible, the agency encourages
patent examiners to classify newly issuing patents as well as previously published patent
documents into the Class 977 cross-reference art collection subclasses . . . .”135 An
individual examiner may take the initiative to reclassify an already issued patent, but time
constraints and meager salaries counsel otherwise. This may cause problems down the
road in litigation, as Part IV illustrates.
¶46
The third limitation is that the information, once the patent is placed in the class
and given a subclassification for cross-referencing, is not tracked or otherwise effectively
utilized to identify patterns that may be playing out in the resulting marketed products or
relationships to other issued patents. The USPTO’s efforts serve as an example for other
federal agencies in terms of gathering information relevant to nanotechnology and
categorizing nano-specific features that could be useful in the future as more becomes
known about the potential products, uses, and risks of nanotechnology. This information
would be particularly useful to regulatory agencies overseeing the resulting products,
such as the FDA. For example, as the Appendix reflects, there is often a disconnect
between scientific research findings, information provided to the FDA for approval
purposes, and what is actually presented to the public about the nanotechnology involved
in commercial products. Utilization and effective linking of this information among
agencies could serve as a mechanism to fill in the information gaps currently confronting
other relevant agencies.
¶47
Despite the nascent state of patent litigation involving the scale or characteristics of
nanotechnology, the scholarly literature has identified several concerns that will emerge
as patenting continues that tie into the three limitations described above. The first major
concern is that overlapping claims will result from broad claiming of scale in early
patents coupled with more precise scale claims linked to particular properties and
functions in later patents. For example, early patent claims may conflate the macro,
micro, and nanoscale in a manner that is problematic for later inventions that identify and
harness something present at a range in the nanoscale but not at the micro or macro scale.
Another concern is the convergence of technologies at the nanoscale, in that overlapping
patents and claims may cross multiple technologies, with many issued before nano was a
widespread word. Many of these concerns will abate given the USPTO’s classification
134

OFFICE OF PHARM. SCI., CTR. FOR DRUG EVALUATION & RESEARCH, MANUAL OF POLICIES AND
PROCEDURES, § 5015.9 REPORTING FORMAT FOR NANOTECHNOLOGY-RELATED INFORMATION IN CMC
REVIEW 3 (2010), available at
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/UCM2143
04.pdf [hereinafter NANOTECHNOLOGY MAPP].
135
Class 977 Nanotechnology Cross-Reference Art Collection, supra note 4.
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system as patenting moves forward, although questions will arise with regard to
inventions submitted and patents issued prior to the development of the classification
system. In performing the cross-listing classifications, the USPTO is merely putting
issued patents into those 263 subclasses and not making determinations on claim scope
and potential infringement from one patent to the next, except as part of the evaluation of
prior art.
¶48
Part IV explores how the limitations in the USPTO’s classification system play out
in the courtroom by describing litigation involving a blockbuster nanotechnology-enabled
treatment for cancer. This litigation highlights the problems posed by nanotechnology:
the limitations of current definitions of nanotechnology; the critical aspects of size,
properties, and characteristics at the nanoscale; and the importance of specificity in the
scope of claim drafting. While this case is the first of its kind, the influx of
nanotechnology patent applications into the USPTO over the last decade (as well as the
thousands of issued patents classified as nanotechnology by reviewers for prior art
purposes) suggests that similar litigation targeting the scope of nanotechnology claims
will be forthcoming.
IV. “NANOTECHNOLOGY” IN COURT: ELAN PHARMA V. ABRAXIS BIOSCIENCE
¶49

Nanotechnology-specific issues have yet to loom large in the context of patent
litigation. A targeted search of legal cases identifies very few patent disputes resulting in
litigation that relate to the nano-size or characteristics of the invention at the nanoscale.136
Most cases that include a reference to nano consist of non-patent allegations, including
breach of contract, licensing issues, or trademark or copyright issues regarding a
company name or product.137 However, one high profile case in the realm of
nanobiotechnology, Elan Pharma v. Abraxis Bioscience,138 is particularly on point and
instructive. The case exemplifies problems regarding scale range and lack of uniformity
in patent claim drafting, the relationship between earlier non-nanotechnology classified
patents and later nanotechnology classified patents, and the struggle in the courtroom by
judges and juries to provide resolution to thorny scientific and technical issues. The case
and the relevant patents are described below.
A. The Patent Litigation

¶50

Elan Pharma v. Abraxis Bioscience involved Abraxane, the Abraxis Bioscience
blockbuster drug for treatment of breast cancer, approved by the FDA in 2005 for
treatment of metastatic breast cancer and marketed widely. Sales generated $314.5
million in 2009.139 Abraxane, the alleged infringing product, is the albumin formulation
of paclitaxel, a cancer-fighting agent that has been used in FDA-approved drugs, such as
136

A search of Westlaw state and federal cases retrieved forty-four cases. Search conducted June 2011.
However, cases involving nanotechnology that do not utilize the term nanotechnology will not be
identified by a search of case law resources, nor will litigation that has not progressed to the stage of
reporting in an official reporter.
138
Elan Pharma Int’l Ltd. v. Abraxis Bioscience Inc., No. 06-438 GMS, 2007 WL 6382930 (D. Del. Dec.
17, 2007).
139
Jessica Merrill, Celgene Moves into Solid Tumors with $2.9 Billion Abraxis Acquisition, PINK SHEET:
PRESCRIPTION PHARMACEUTICALS & BIOTECHNOLOGY, July 5, 2010, at 11.
137
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Taxol, for years.140 In addition to allowing the faster administration of the drug (thirty
minutes as opposed to three hours for the previous formulation, Taxol), the albuminbound formulation “eliminates the need for a solvent that can be toxic and also means
greater doses of paclitaxel can be given before side effects become intolerable.”141
¶51
The jury determined that Abraxane infringed on several of Elan’s patent claims in
U.S. Patent No. 5,399,363 (’363 Patent),142 issued by the USPTO in 1995. The Elan ’363
Patent claimed anticancer compositions in the form of “surface modified nanoparticles”
in “crystalline” form that “exhibit reduced toxicity and/or enhanced efficacy.”143 The
Elan Patent specifically claimed:
Particles consisting essentially of 99.9% by weight of a crystalline
medicament useful in treating cancer susceptible to treatment with said
medicament, said medicament having a solubility in water of less than 10 mg/ml,
and having a non-crosslinked surface modifier adsorbed on the surface thereof in
an amount of 0.1–90% by weight and sufficient to maintain an average effective
particle size of less than 1000 nm . . . .144

The court determined that the scope of the nanoparticles as claimed required that “90% of
the particles have a number average particle size of less than 1000 nanometers.”145 Other
key terms construed by the court were “surface modifier,” defined as “a substance that
modifies the surface properties of the crystalline medicament,”146 and “non-crosslinked,”
defined as “the individually adsorbed molecules of the surface modifier are essentially
free of intermolecular crosslinkages.”147
¶52
While it was not identical to the Elan Patent, Elan argued that Abraxane infringed
because “more than one particle” out of over 61 trillion nanoparticles in the product were
“entirely crystalline” and “non-crosslinked surface modifiers.”148 Abraxis argued that
Abraxane’s eight percent crystalline form did not require that any specific particle be
entirely crystalline,149 but did acknowledge that the human serum albumin, which is
captured by the ’363 Patent’s definition of “surface modifier,” is adsorbed on the surface
140

The drug ingredient is named paclitaxel; one brand name drug product is called Taxol. See Paclitaxel,
DRUGS.COM, http://www.drugs.com/international/paclitaxel.html (last visited Dec. 19, 2011).
141
Merrill, supra note 139, at 12.
142
Verdict Form at 1, Elan Pharma, No. 06-438 GMS, 2008 WL 2556294. The jury, however, did not find
willful infringement of the ’363 Patent. Id. at 5. The jury also found Elan’s patent 5,834,025 and the ’363
patent not invalid for lack of enablement, failure of written description, or inequitable conduct. Id. at 2–4.
143
Surface Modified Anticancer Nanoparticles, U.S. Patent No. 5,399,363 (filed July 1, 1992) col. 1 l. 45–
50. The listed patent assignee is the Eastman Kodak Company, who licensed the technology to Elan
Pharma for development.
144
Id. at col. 14 l. 7–14. The abstract reads: “Dispersible particles consisting essentially of a crystalline
anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to
maintain an effective average particle size of less than about 1000 nm.” Id. at [57].
145
Order Construing the Terms of U.S. Patent Nos. 5,399,363 and 5,834,025 at 3, Elan Pharma. 06-438
GMS, 2007 WL 6137001 (internal quotation mark omitted).
146
Id. at 2 (internal quotation marks omitted).
147
Id. (internal quotation marks omitted).
148
Defendant Abraxis Bioscience, Inc.’s Opening Brief in Support of Its Motion for Judgment as a Matter
of Law of Noninfringement, Invalidity, Inequitable Conduct, and Its Motion for New Trial at 5–6, 12, Elan
Pharma, No. 06-438-GMS, 2008 WL 2856297 (internal quotation marks omitted).
149
Id. at 2.
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of Abraxane to prevent crosslinking.150 The jury found a sufficient number of the
Abraxane medicament particles were entirely crystalline and thus infringed the ’363
Patent.
¶53
The outcome of the 2008 Delaware district court case was a jury verdict of $55.2
million to Elan Pharma for Abraxis’ infringement of the ’363 Patent issued in 1995.151
The monetary damages amount reflects a six percent royalty on the sales of Abraxane
during the infringement period of January 7, 2005 to June 13, 2008.152 In June 2010,
Celgene acquired Abraxis Bioscience for approximately $2.9 billion in cash and
stocks;153 the acquisition was finalized in October 2010.154 Celgene also agreed to pay
Elan a one-time licensing fee of $78 million when it acquired Abraxis under terms that
Elan will not “receive any additional payments for sales of [Abraxane], or any other
[nab]-Paclitaxel product.”155 It is not clear what terms were negotiated among the parties
regarding the relationship between the ’363 Patent and the pending patent applications at
the USPTO covering the Abraxane product and technology. Part IV-B discusses the two
key patents in more detail.
¶54
Subsequent to the litigation, the USPTO granted Abraxis two patents for its
nanoparticle technology on October 26, 2010156 and April 12, 2011.157 Celgene plans to
initiate a marketing campaign aimed at increasing Abraxane drug sales to $1 billion by
the year 2015.158 Celgene anticipates that Abraxane will retain patent protection and
large profits until 2023,159 likely based on calculations involving the licensing deal from
Elan, which resulted from this litigation, coupled with the recently issued patent for
certain aspects of the technology. Five other drugs are currently in development based on
the nanoparticle technology in Abraxane, including drugs in Phase III clinical trials for
treatment of first-line non-small cell lung cancer and pancreatic cancer.160
¶55
Notably, this case illustrates the limitation inherent in the definition of
nanotechnology as under 100 nm. The USPTO has not classified the Elan Patent in the
977 cross-reference nanotechnology classification, likely because the patent broadly
claims nanoparticles “under 1000 nm” which, while including particle size under 100 nm,
also includes the 101–999 nm range as well.
150

Plaintiff Pharma International Ltd.’s Opening Claim Construction Brief at 5–6, Elan Pharma, No. 06438-GMS, 2008 WL 2856297.
151
William F. Prendergast & Heather N. Schafer, Nanocrystalline Pharmaceutical Patent Litigation: The
First Case, 5 NANOTECHNOLOGY L. & BUS. 157, 157 (2008).
152
Verdict Form, supra note 142, at 5.
153
Andrew Pollack, Prominent Drug Chief to Sell Abraxis BioScience to Celgene for $2.9 Billion, N.Y.
TIMES, July 1, 2010, at B3; Press Release, Celgene Corp., Celgene to Acquire Abraxis BioScience Inc.
(June 30, 2010), http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1442901.
154
Press Release, Celgene Corp., Celgene Completes Acquisition of Abraxis (Oct. 15, 2010),
http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1483257.
155
Elan and Celgene Enter into Settlement and License Agreement Related to ABRAXANE, BUSINESS
WIRE, Feb. 24, 2011, available at http://www.businesswire.com/news/home/20110224007229/en/ElanCelgene-Enter-Settlement-License-Agreement-Related.
156
’788 Patent.
157
Compositions & Methods of Delivery of Pharmacological Agents, U.S. Patent No. 7,923,536 B2 (filed
Apr. 12, 2010).
158
Merrill, supra note 139, at 11.
159
Id. at 12.
160
Id. Other investigations include refractory invasive bladder cancer and malignant melanoma.
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B. The Patents
¶56

The 1995 Elan Patent and the subsequently issued Abraxis Biosciences patents
illustrate what is sure to be an increasingly problematic aspect of nanotechnology
patenting—claim scope and drafting. Both patents claim characteristics and interactions
of serum albumin and Taxol, an anti-cancer agent. The relationship between the two
patents warrants a brief primer.
¶57
Taxol (paclitaxel) is a molecule that contains many non-polar (hydrophobic) carbon
rings that share electrons equally, causing the solubility of Taxol in water to be
significantly reduced and inhibiting its effectiveness as a cancer therapy.161 The protein
serum albumin, a molecule having both hydrophobic and hydrophilic properties, can be
used as a surface modifier to enhance the solubility of Taxol. Non-polar domains interact
with Taxol, and the polar (hydrophilic) domains interact with water.162 Due to its dual
nature, albumin will self-assemble on a Taxol particle and create a shell of albumin,
coating the Taxol particle, whereby hydrophobic Taxol is insulated from water and other
Taxol particles.163 The albumin thus prevents the aggregation of multiple Taxol particles
and enhances the solubility in water.164 Both the Elan Patent and the Abraxane Patents
rely on the Taxol and serum albumin interaction at the nanoscale.
1. The Elan ’363 Patent
¶58

The Elan ’363 Patent is drafted extremely broadly. Claim 1 covers any particles
that have an average size of less than 1,000 nm and are composed of one of the named
poorly water-soluble anti-cancer medications and any adsorbed surface coating.165 Claim
1 gives specific examples of the types of medication and includes Taxol in this list.166
The use of Taxol for the specific purpose of an anti-cancer agent is stated in Claim 5.167
Beginning with Claim 12 of the ’363 Patent, the different types of surface modifiers are
listed.168 Claim 12 is especially broad because it covers any surface modifier that is “a
surfactant.”169 Surfactants are an entire class of small molecules that have both
hydrophobic and hydrophilic properties. Claim 15 goes on to state other specific surface
modifiers including bovine serum albumin,170 which contains hydrophobic and
hydrophilic domains.
¶59
This patent is not classified by the USPTO as within the 977 nanotechnology crossreference system, due to both procedural and substantive reasons mentioned in Part III.
On the procedural side, there is no retroactive classification of issued patents into the 977
161

For a primer on hydrophobic and hydrophilic interactions, see BRUCE ALBERTS ET AL., MOLECULAR
BIOLOGY OF THE CELL 57–58 (4th ed. 2002).
162
Toru Takagishi, Amphiphilic Polymers (Binding Properties for Small Molecules), in 1 POLYMERIC
MATERIALS ENCYCLOPEDIA 228, 228 (Joseph C. Salamone ed., 1996).
163
A.G. Garro et al., Reversible Exposure of Hydrophobic Residues on Albumin as a Novel Strategy for
Formulation of Nanodelivery Vehicles for Taxanes, 6 INT’L J. NANOMEDICINE 1193, 1193 (2011).
164
Id.
165
See ’363 Patent col. 14 l. 7.
166
Id.
167
Id. at col. 14 l. 35.
168
Id. at col. 14–15.
169
Id. at col. 14 l. 68.
170
Id. at col. 15 l. 5.
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cross-reference system. Individual patent examiners may initiate reclassification.
Coupled with examiner discretion, the Elan Patent was filed back in 1992 and issued in
1995.171 Its expiration is quickly approaching, likely making it an unpopular candidate
for reclassification energy.
¶60
On the substantive side, the USPTO’s definition of nanostructure may limit
inclusion of certain patents including the Elan Patent. Based on physical dimension
requirements alone, the Elan particles could simply be too large. The ’363 Patent claims
surface modified particles in crystalline form in the range of less than 1,000 nm,172 less
than 400 nm,173 and less than 300 nm.174 While each of the three claimed particle sizes
may be within the 1–100 nm range, they might not be. Examples in the patent that
illustrate the invention identify the smallest final particle size to be 240 nm.175
2. The Abraxis ’788 Patent
¶61

Unlike the Elan Patent, the Abraxis Patent has been classified as a nanotechnology
patent by the USPTO. The patent’s primary classification is denoted as 530/350 and the
nanotechnology subclassification is 977/779 (nanotechnology; nanostructure; within
specified host or matrix material; possessing nano-sized particles, powders, flakes, or
clusters other than simpler atomic impurity doping); 977/906 (nanotechnology; specified
use of nanostructure; drug delivery); and 977/911 (nanotechnology; specified use of
nanostructure; for medical, immunological, body treatment, or diagnosis; mechanical
repair performed; surgical; cancer cell).176
¶62
The scope of the ’788 Patent is much narrower, but it appears that there is some
overlap with the ’363 Patent regarding the nanoparticle composition. Claim 1 of the
Abraxis Patent claims
A pharmaceutical composition for injection comprising paclitaxel and a
pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable
carrier comprises albumin, wherein the albumin and the paclitaxel in the
composition are formulated as particles, wherein the particles have a particle size
of less than about 200 nm, and wherein the weight ratio of albumin to paclitaxel
in the composition is about 1:1 to about 9:1.177

There are eleven subsequent claims.
¶63
In ’788, the only anti-cancer compound claimed is paclitaxel,178 the only surface
modifier is human serum albumin,179 and the average particle size is limited to less than
200 nm.180 As compared to the Elan ’363 Patent, there are arguably areas of overlap.
171

Id. at [22], [45].
Id. at col. 14 l. 14.
173
Id. at col. 14 l. 29.
174
Id. at col. 14 l. 31.
175
Id. at col. 8 l. 28, col. 9 l. 63.
176
’788 Patent. This Part analyzes the earlier issued patent, as the later patent (’536 Patent) is subject to a
terminal disclaimer.
177
Id. at col. 38 l. 17–24.
178
Id. at col. 38 l. 18.
179
Id. at col. 38 l. 25.
180
Id. at col. 38 l. 22.
172
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Taxol (paclitaxel) was specifically mentioned as a possible anti-cancer compound in the
’363 Patent. The average particle size of less than 200 nm in the ’788 Patent would fall
within the average particle size of less than 1,000 nm (and less than 400 and 300 nm) in
the ’363 Patent, and bovine serum albumin was specifically mentioned as a surface
modifier in the ’363 Patent.181
FIGURE 2. COMPARISON OF KEY CLAIMS IN THE ’363 AND ’788 PATENTS
Patent Claims

’363 Patent182

Particle Size & Ranges

“Average effective particle size” of < 1,000
nm; < 400 nm; < 300 nm

Agents
Surface modifiers
Indications
Route of
Administration

“anti-cancer agents”; claims taxol among
others
Any surface modifier that is a “surfactant”;
claims bovine serum albumin among others
“anticancer agent”
“administer[ed] to a mammal”

’788 Patent183
“particle size [of paclitaxel and
albumin] of less than about 200
nm”
paclitaxel
human serum albumin
Cancer, arthritis, restenosis
Various, including intravenous,
orally, etc.

C. Reconciling the ’363 and ’788 Patents
¶64

A comparison of the two patents described in Parts IV-A and IV-B illustrate the
problems that courts, the USPTO, and industry will face as nanotechnology development
pushes forward. This Part raises a number of comparative points in order to frame Part
V; this is not intended to be an exhaustive analysis of the patents, and the author
acknowledges that this is a cursory look rather an in-depth examination.
¶65
The particle range of the claims is significant to the discussion of the novel
properties that emerge at the nanoscale. In the ’363 Patent, all examples provided within
the patent exceed 240 nm; in the ’788 Patent, all examples provided in the patents are
within the range of 50 to 220 nm, a range starting squarely under the 100 nm outer
bounds range set forth by the USPTO. Another critical aspect that came to light in the
litigation is the surface modifier form; the ’363 Patent claims non-crosslinked surface
modifiers that include those in “crystalline form.” This was at the heart of the litigation
regarding Abraxane’s mechanism of action and drug form. The patents seemingly
overlap in a number of regards: both claim in the size range greater than 200 nm, both
claim either the agent Taxol or paclitaxel, and both claim a form of serum albumin as an
agent, though the ’536 Patent claims are limited to cancer, arthritis, and restenosis.184
¶66
In contrast to the Elan Patent, the Abraxis Patent claims average particles sizes less
than 200 nm185 and example preparations provide an average range for the particle rather
than a final particle size as presented in the Elan Patent. For instance, Example 12 of the
Abraxis Patent describes preparation of particles “in the range 50–220 nm.”186 While it is

181

Cf. infra Figure 2.
'363 Patent col. 14–15.
183
’788 Patent col. 38.
184
’536 Patent col. 37.
185
See supra Figure 2.
186
’788 Patent col. 19 l. 20.
182
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unclear, perhaps the claim is drafted so that the nanoparticle size is sufficiently small to
impart special diffusion properties not present at the scale offered in the Elan Patent.
¶67
Additionally, the distinction between bovine serum albumin and human serum
albumin may or may not be significant. Claim 2 of the ’788 Patent covers human serum
albumin187 (HSA) as the surface modifier, rather than the bovine serum albumen (BSA)
claimed in the ’363 Patent.188 HSA and BSA share seventy-six percent identical amino
acids and approximately eighty-seven percent of the amino acids are either identical or
have similar chemical properties.189 This degree of sequence homology suggests that
HSA and BSA are interchangeable for constitution of soluble nanoparticles that do not
aggregate, though it is unclear if this is the case when utilized in a human.
¶68
Parts III and IV argue that the USPTO nanotechnology classification, while a
laudable effort, is not performing as well as it could to quell the impending problems that
will confront the patent system. Part V details a research agenda of possible steps that
could improve outcomes for nanotechnology patenting.
V. A RESEARCH AGENDA
¶69

This Article presents three core challenges facing the USPTO and reviewing courts
as nanotechnology develops and litigation emerges: (1) limitations of and inconsistencies
among current definitions of nanotechnology; (2) uncertainty and lack of uniformity in
measurement capabilities regarding critical aspects of size, properties, and characteristics
at the nanoscale; and (3) the role of patent claims in accurately and consistently
encapsulating and distinguishing the scope of nanotechnology inventions. Keying in on
the third problem, this Part suggests mechanisms to more effectively utilize the 977
classification system, learning from experience and case law in other scientific and
technological areas, scholarly criticisms of the patent system as applied to
nanotechnology, and the Abraxane litigation and related patents.
A. Improve the Internal 977 Process

¶70

The lowest-hanging fruit is, of course, to recommend that the USPTO reassess the
977 classification system and develop improvements to the system. These improvements
can come in two forms: substantive and procedural. One major substantive improvement
187

Id. at col. 38 l. 25.
See ’363 Patent col. 16 l. 8.
189
These results were reached utilizing both the European Bioinformatics Institute EMBOSS Needle online
tool and the protein sequence database on the National Center for Biotechnology Information’s website.
EMBOSS is a bioinformatics tool that can be used to create an optimal alignment between two proteins that
have similar, but not identical, amino acid sequences. The program uses the Needleman-Wunsch algorithm
and a pre-determined scoring matrix to create the alignment; the resulting optimal alignment is displayed
graphically along with the percentage of identical and chemically similar amino acids between the two
proteins. See EMBOSS Needle: Pairwise Sequence Alignment, EUR. BIOINFORMATICS INST.,
http://www.ebi.ac.uk/Tools/psa/emboss_needle/ (last visited Dec. 19, 2011). First, users should obtain the
protein sequences for HSA and BSA. E.g., Protein Database, NAT’L CTR. FOR BIOTECHNOLOGY INFO.,
http://www.ncbi.nlm.nih.gov/protein/ (last visited Dec. 19, 2011) (accessed by searching for “178344” and
“3336842,” the unique identifiers for HSA and BSA, respectively, and clicking “FASTA”). Users should
then paste the resulting sequences into EMBOSS (one in “first protein sequence” and the other in “second
protein sequence”) to compare the two sequences. EMBOSS Needle: Pairwise Sequence Alignment, supra.
188
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would be to revisit the definition and qualifications for inclusion into the 977
classification. As evidenced in the pharmaceutical realm, many products utilizing
nanotechnology may exceed the rigid 100 nm ceiling and are, in fact, legitimately
nanotechnology as a scientific and technical matter. This is the stance recently taken by
the FDA’s Center for Drug Evaluation and Research and the Research Office of
Pharmaceutical Science (CDER). In May 2010, CDER jointly issued an internal Manual
of Policies and Procedures (MaPP) instructing drug reviewers to capture relevant
information pertaining to “nanomaterial-containing drugs” and to organize data into a
nanotechnology database.190 This MaPP describes the terms nanomaterial and nanoscale
material as involving “[a]ny materials with at least one dimension smaller than 1,000
nm.”191 The 1 to 1,000 nm range included in CDER’s conception of nanoscale as
compared to both the NNI and USPTO definitions extending from 1 nm to 100 nm
implies that the FDA has determined, as many scientists have argued for years, that
nanotechnology is not necessarily capped at 100 nm, as the size-dependent novel
properties vary with the material, environment, and interactions.192
¶71
On the procedural side, a second improvement would be to tackle retroactive
classification of patents applications submitted before 2004. The USPTO should
establish an internal task force to discuss such an action, particularly identifying priority
sub-classifications and proper scope and application of the retroactivity. For example,
patents that have expired would be less of a priority as challenges to those patents would
not be forthcoming. The task force should also consider prioritizing scientific and
technical areas with the most active patent litigation.
B. Collaborate with Other Agencies
¶72

Inextricably tied to the first suggestion regarding internal improvements, the
USPTO should also strive to improve not only the internal functioning of the 977
classification system, but also its interoperability with other relevant regulatory agencies.
Although useful within the USPTO, this system of classification and wealth of
nanotechnology-specific information could be more broadly shared and utilized by other
relevant administrative agencies as they tackle the inherent challenges of nanotechnology
and nanomedicine specifically. The USPTO should develop mechanisms to collaborate
with other agencies, specifically the FDA, to extend the utility of their informationgathering and classification efforts. For purposes of this Article, the FDA is a prime
example of a regulatory agency that would benefit from improvements in the USPTO
process and joint collaboration efforts. Given the close relationship between patents and
pharmaceutical development, enhanced feedback mechanisms between the FDA and
USPTO would assist in a variety of ways.
¶73
Perhaps most helpful would be active collaboration between the USPTO and FDA
regarding patent disclosures for purposes of listings in the Orange Book. As a key
resource for generic drug companies in developing bioequivalent versions of pioneer

190

NANOTECHNOLOGY MAPP, supra note 134, at 1.
Id. at 3.
192
See Paradise, Reassessing ‘Safety’ for Nanotechnology, supra note 2.
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drugs,193 the Orange Book provides all relevant patents that the generic sponsor must
consider when developing the generic drug and filing for FDA approval. The Appendix
reveals that very few nanodrugs disclose patents that have been classified by the USPTO
as nanotechnology, suggesting an apparent disconnect between the information presented
to the FDA and information presented to the USPTO or, as discussed earlier, a difference
in defining nanotechnology. As a means to more effectively track nano-specific features
and outcomes of nanodrugs, some type of feedback mechanism or cross-reference system
between the two agencies would bolster transparency and foster uniformity in the drug
industry with regard to information disclosure in the patent application process and
eventual FDA application for market approval.
¶74
The USPTO should also build on the actions of other agencies in providing
guidance to industry on nanotechnology issues. The FDA would be an ideal ally for the
USPTO in this respect, as the FDA has possibly been the most proactive agency in terms
of identifying regulatory challenges to the existing oversight system.194 The FDA has
thus far formed a multi-center task force,195 instituted a drug specific internal policy,196
published draft guidance for industry,197 solicited public comments through public
meetings,198 and partnered with research institutions to examine particular aspects of
nanotechnology.199 In particular, development by the USPTO of a document similar to
the FDA’s draft guidance to industry may be especially helpful to patent applicants when
contemplating whether to specifically describe their inventions in the nanoscale range. A
“how to” for applicants would assist in more uniformity at the inventor and claim level.
C. Provide Training and Resources for Examiners
¶75

Any critique of the USPTO necessarily entails some treatment of patent examiner
expertise, credentials, and performance. As nanotechnology is a confluence of

193

The requirements and framework of the generic drug approval process is found in 21 U.S.C. § 355(j)
(2006). A showing of bioequivalence requires “the absence of a significant difference in the rate and extent
to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives
becomes available at the site of drug action when administered at the same molar dose under similar
conditions in an appropriately designed study.” 21 C.F.R. § 320.1(e) (2010).
194
See Paradise, Reassessing ‘Safety’ for Nanotechnology, supra note 2.
195
U.S. FOOD & DRUG ADMIN., NANOTECHNOLOGY TASK FORCE, NANOTECHNOLOGY: A REPORT OF THE
U.S. FOOD AND DRUG ADMINISTRATION NANOTECHNOLOGY TASK FORCE 20–21 (2007), available at
http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/Nanotechnology/ucm110856.pdf.
196
NANOTECHNOLOGY MAPP, supra note 134.
197
Draft Guidance for Industry: Considering Whether an FDA-Regulated Product Involves the Application
of Nanotechnology, 76 Fed. Reg. 34,715 (June 14, 2011); see also FDA Draft Guidance Questions and
Answers, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm258391.htm (last updated June 9,
2011); News Release, U.S. Food & Drug Admin., FDA Takes ‘First Step’ Toward Greater Regulatory
Certainty Around Nanotechnology (June 9, 2011),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm258377.htm.
198
Consideration of FDA-Regulated Products that May Contain Nanoscale Materials, 73 Fed. Reg. 46,022
(Aug. 7, 2008).
199
Nanotechnology Partnerships at FDA, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm208110.htm (last updated July
22, 2010).
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disciplines, very few patent examiners have advanced degrees in nanotechnology.200
Acknowledging the high turnover of patent examiners, less than ideal wages, and heavy
workloads, the USPTO can take certain actions to address issues with delivery of
information to patent examiners. First, the USPTO should contract with disinterested
outside parties to train and educate patent examiners on nanotechnology and
nanotechnology patent drafting. In November 2004, the USPTO established a working
group consisting of outside lawyers and scientists to provide guidance to key figures as
the USPTO began training examiners in nanotechnology concepts and terminology.201 It
is unclear how this working group has been utilized to date. Other sources report that
some select law firms that supply counsel to the nanotechnology industry are hosting
educational sessions for patent examiners. For example, Burns, Doane, Swecker &
Mathis, LLP began a monthly forum to provide nanotechnology education to
examiners.202 Such arrangements raise potential conflicts of interest and should possibly
be avoided by the USPTO.
¶76
The USPTO should pursue partnerships with the NNI, which is the federal vehicle
for nanotechnology funding and development. Placed within the National Science and
Technology Council as a national coordinating entity for nanotechnology research,
development, and education, the NNI is made up of twenty-five federal agencies.203 The
NNI serves as coordinating entity for agencies dealing with nanotechnology and fosters
collaborative efforts in research and education among the agencies.204 A direct
partnership between NNI and the USPTO in training and resources would help feed
cutting-edge research findings and processes into patent examiners for consideration
when reviewing patent applications and classifying them.
D. Utilize the Patent Peer Review Pilot Program
¶77

The USPTO implemented a pilot program to gather information on peer-reviewed
publications and research in the public domain to locate “prior art that might not
otherwise be located by the USPTO during the typical patent examination process.”205
The original pilot program began in 2007 and lasted two years,206 returning evidence that
the public is “capable of contributing to the location of prior art of value to the examiner
during the examination process.”207 The scope of the initial pilot program was limited to
patent applications in computer-related arts.208 The project was then expanded to include
patent applications in Class 705, “Data Processing: Financial Business Practice,

200

See, e.g., Where Science and Law Meet, supra note 117, at 3.
Feder, supra note 103.
202
Patent Office Struggles to Stay Ahead of Nanotech Industry, supra note 118.
203
NAT’L SCI. & TECH. COUNCIL, SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., NATIONAL
NANOTECHNOLOGY INITIATIVE STRATEGIC PLAN 1 (2011), available at
http://www.nano.gov/nnistrategicplan211.pdf.
204
See, e.g., id. at 35.
205
Peer Review Pilot FY2011, U.S. PAT. & TRADEMARK OFF.,
http://www.uspto.gov/patents/init_events/peerpriorartpilotindex.jsp (last updated May 31, 2011).
206
Id.
207
Id.
208
Id.
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Management, or Cost/Price Determination.”209 Out of the total 189 applications accepted
into the program, thirty applications had at least one claim rejected based on prior art
contributed by the public.210 In fifteen of those thirty applications, the patent examiner
did not find the prior art used to ultimately reject the claim.211
¶78
The USPTO expanded the program again in October 2010, which will continue
through September 2011.212 As described by the USPTO:
In addition to statistical data on participation rates and the number of
prior art references found and utilized by the USPTO, this pilot will be evaluating
the effectiveness of the process more closely as it relates to patent examination
efficiency and quality and peer participation behaviors. This pilot will test
whether a peer review process is a viable addition to the normal processes of the
USPTO and as an option for applicants to choose among the other products
offered by the USPTO.213

Although the additional pilot program expansion includes several patents areas, including
several primary drug classifications, the 977 classification is not included. Several of the
drug classifications, however, may implicate an overlap with nanotechnology, such as
424/514 (Drug, Bioaffecting and Body treating compositions).214 As previously
discussed, many drugs utilizing nanotechnology are currently on the market or in
research and development stages.
¶79
The USPTO should consider using the peer review pilot as a mechanism to gather
nanotechnology-specific information and prior art from stakeholders outside the USPTO.
Particularly cueing in on nanopharmaceuticals, the USPTO should select a set of
nanotechnology subclassifications to present as the next phase of the pilot program.
VI. CONCLUSION
¶80

Nanotechnology is no longer a forecast. It has arrived in basic consumer products,
environmental remediation, electronics, mechanics, energy, optics, computing and
information technology, industrial manufacturing, and health care and medicine. The
resulting innovations and inventions are beginning to inundate the USPTO, an agency
still trying to grapple with the patent ramifications of genetics over a decade after the
completion of the Human Genome Project. The USPTO’s newly created 977
nanotechnology classification aims to organize nanotechnology patents into relevant subclassifications for ease in prior art searches and uniformity in cross-referencing. The
USPTO system installs a collection of patents and patent applications that share the
209

John Doll, Extension and Expansion of Pilot Concerning Public Submission of Peer Reviewed Prior Art,
1333 OFF. GAZ. PAT. & TRADEMARK OFF. 103 (2008),
http://www.uspto.gov/web/offices/com/sol/og/2008/week33/TOC.htm#ref13
210
David J. Kappos, A New Pilot Program Concerning Public Submission of Peer Reviewed Prior Art,
1361 OFF. GAZ. PAT. & TRADEMARK OFF. 230, 230 (2010),
http://www.uspto.gov/web/offices/com/sol/og/2010/week52/TOC.htm#ref15.
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Id.
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Peer Review Pilot FY2011, supra note 205.
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Kappos, supra note 210, at 235.
214
Eligible Classes and Subclasses for the Peer Review Pilot 2011, U.S. PAT. & TRADEMARK OFF.,
http://www.uspto.gov/patents/init_events/class_subclasses_FY2011pilot.jsp (last updated Jan. 4, 2011).
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common feature of falling within the nanotechnology penumbra—inventions at the
nanoscale that exhibit unique features because of their 1–100 nm size. Despite the
laudable effort, the classification system suffers from serious shortcomings.
¶81
This Article argues that as nanotechnology development and patenting progresses,
three core problems will continue to raise challenges for the USPTO and courts: (1)
limitations of and inconsistencies among current definitions of nanotechnology; (2)
uncertainty and lack of uniformity in measurement capabilities regarding critical aspects
of size, properties, and characteristics at the nanoscale; and (3) the role of patent claims
to accurately and consistently encapsulate and distinguish the scope of nanotechnology
inventions. Careful examination of Elan Pharma v. Abraxis Bioscience215 helps to
illustrate these three inherent problems and the related shortcomings of the USPTO
nanotechnology patent classification system. Tying this case to U.S. patent law and
policy, case precedent, and practice of the USPTO, we can extract lessons to apply to the
emerging realm of nanopharmaceuticals.
¶82
Drawing from this analysis, a variety of adjustments would serve to assist the
USPTO in fulfilling its mission to foster and award innovation while also facilitating
effective information gathering to feed into regulation of the resulting products and
inform any ensuing patent infringement litigation. These include improvements to the
existing nanotechnology classification process, increasing feedback and collaboration
with other federal agencies relevant to nanotechnology inventions, instituting
independent educational programs for patent examiners, and utilizing the pilot peer
review system for nanotechnology applications to encourage broader dialogue on the
scope of patent claims and relationships to already issued patents.

215

No. 06-438 GMS, 2007 WL 6382930 (D. Del. Dec. 17, 2007).
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Appendix: FDA-Approved Drugs Utilizing Nanoscale Properties or Materials
Product

Indicationsi

Companyii

Formulation
Description

Original
NDA
Approvaliii

U.S.
Patent
No.iv

977 Nano
subclass

Zoladex

Anti-cancer
drugv

AstraZeneca

Polymer rods
used as
nanocarriervi

12/29/89*

7,118,552;
7,220,247;
7,500,964

None

Adagen

Immunodeficien
cy diseasevii

Sigma Tau

PEG-adenosine
deaminaseviii

3/21/90*

None

None

Lipid
regulationix

Abbott

Nanocrystalline
fenofibratex

12/31/93xi

5,145,684;
6,277,405;
6,375,986i;
6,652,881;
7,037,529;
7,041,319;
7,276,249;
7,320,802

Doxil

Anti-cancer drug
for metastatic
ovarian and
breast cancers,
and HIV-related
Kaposi’s
sarcomaxii

OrthoBiotech
Products, LP

Liposomal
doxorubicinxiii

11/17/95*

None

None

Abelcet

Fungal
infectionsxiv

Sigma Tau

Amphotericin
B/lipid complexxv

11/20/95*

5,616,334;
6,406,713

None

DaunoXome

HIV-related
Kaposi’s
sarcomaxvi

Gilead

Nano-sized drug
for treatment of
solid tumorxvii

4/8/96*

None

None

Feridex

In vivo imaging
of liver
tumorsxviii

AMAG
Pharms Inc.

Iron
nanoparticlesxix

8/30/96*

5,248,492

None

Amphotec

Fungal
infectionsxx

Aldopharma
USA

Amphotericin
B/lipid colloidal
dispersionxxi

11/22/96*

None

None

Gastromark

Used for
improved
imaging of
abdominal
structuresxxii

AMAG
Pharms Inc.

Nano-sized
contrast agentxxiii

12/6/96*

None

None

Ambisome

Fungal
infectionsxxiv

Astellas

Liposomal
Amphotericin
Bxxv

8/11/97

5,874,104;
5,965,156

None

Tricor
(discontinued)

i

773; 896
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Indicationsi

Companyii

Formulation
Description

Renagel

Chronic kidney
diseasexxvi

Genzyme

Crosslinked
poly(allylamine)
resinxxvii

Depocyt

Treatment of
lymphomatous
meningitis

Pacira

Liposomal
cytarabinexxviii

Rapamune

Immunosuppress
ant for
prevention of
organ rejection

Visudyne

Copaxone

Somavert

Emend
(Aprepitant)

204

Age-related
macular
degenerationxxx

Multiple
sclerosisxxxii

Acromegalyxxxiv

Prevents nausea
and vomiting
induced by
chemotherapy

Wyeth

QLT

TEVA

Pharmacia &
Upjohn

Merck &
Co.¥

Nanocrystalline
sirolimusxxix

Liposomal
verteporfinxxxi

Copolymer of
alanine, lysine,
glutamic acid, and
tyrosinexxxiii

PEG-HGHxxxv

Nanocrystalline
aprepitantxxxvi

Original
NDA
Approvaliii

U.S.
Patent
No.iv

977 Nano
subclass

10/30/98

5,496,545;
5,667,775;
6,509,013;
6,733,780;
7,014,846;
7,459,151

None

4/1/99

5,455,044i;
5,723,147

907;
911; 915

9/15/99

5,100,899;
5,145,684;
5,212,155;
5,403,833;
5,989,591

None

4/12/00

5,095,030;
5,707,608;
5,756,541;
5,770,619;
5,798,349;
6,074,666

None

2/12/02*

5,981,589;
6,054,430;
6,342,476;
6,362,161;
6,620,847;
6,939,539;
7,199,098

None

3/25/03

5,350,836;
5,681,809;
5,849,535;
5,958,879;
6,057,292;
6,583,115

None

3/26/03

5,145,684;
5,538,982;
5,719,147;
6,048,859;
6,096,742;
6,235,735;
7,214,692

None

(accelerated
approval)

i
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Product

Indicationsi

Companyii

Formulation
Description

Original
NDA
Approvaliii

U.S.
Patent
No.iv

977 Nano
subclass

Estrasorb

Menopausal
therapyxxxvii

Graceway

Estradiol in
micellar
nanoparticlesxxxviii

10/9/03

5,629,021

773; 915;
926
729;
773; 775;
896; 906;
915
ii
779;
906
iii
779;
906; 911
iv
700;
904

Abraxane

Anti-cancer drug
for treatment of
metastatic breast
cancerxxxix

Abraxis
Bioscience

Albumin-bound
paclitaxelxl

1/7/05

5,439,686;
5,498,421;
6,096,331;
6,506,405;
6,537,579i;
6,749,868;
6,753,006;
7,820,788ii;
7,923,536iii
;
RE41,884iv

Triglide

Lipid
regulationxli

SkyePharma

Nanocrystaline
fenofibratexlii

5/7/05

6,696,084

None

MegaceES

Eating
disordersxliii

Par Pharm

Nanocrystalline
megesterol
acetatexliv

7/5/05

5,145,684;
6,592,903;
7,101,576

None

Emend
(fosaprepitant
dimeglumine)

Prevents nausea
and vomiting
induced by
chemotherapy

1/25/08

5,512,570;
5,538,982;
5,691,336;
5,716,942;
7,214,692

None

Merck &
Co.¥

Nano-sized drug
molecules

i
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Special thanks to Research Assistant Ethan Fitzpatrick, Ph.D., a Seton Hall University School of Law
second year law student, for constructing this Appendix. These products were identified by a two-pronged
search methodology: a search of the relevant scientific literature reporting on research and development in
nanopharmaceuticals and the FDA’s website providing information on FDA-approved drugs. See
Drugs@FDA Database, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/InformationOnDrugs/ucm135821.htm (last updated June 18, 2009). Where a
product was identified in the scientific literature as a nanopharmaceutical, the FDA database was used to
retrieve that products approval information. Searches were conducted January 2011 through May 2011.
The references below provide all scientific sources identified in the search.
Roman numerals indicate a direct link between a specific patent (in the “U.S. Patent No.” column)
and the USPTO classifications within that patent (in the “Classification” column).
*Approval letters not available.
¥ Uses Elan Corporation’s NanoCrystal Technology.
i

Drug indications were identified utilizing the approval letters posted at the FDA’s drug search
database. Search by Drug Name, Active Ingredient, or Application Number, U.S. FOOD & DRUG ADMIN.,
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (last visited Dec. 19, 2011). Where the
original approval letters were not available at the drug search database, the table notes this with an asterisk
in the “Original NDA Approval” column and secondary sources for indications are identified in that drug’s
informational row.
ii

Company information was accessed using the FDA’s drug search database. Id.

iii

New Drug Applications (NDAs) are submitted to and approved by the FDA.

iv

Patent information was accessed using the FDA’s electronic listings of the Orange Book: Approved
Drug Products with Therapeutic Equivalence Evaluations, U.S. FOOD & DRUG
ADMIN.,http://www.accessdata.fda.gov/scripts/cder/ob/docs/querytn.cfm (last visited Dec. 19, 2011).
v

K.K. Jain, Advances in the Field of Nanooncology, BMC MED., Dec. 13, 2010, at 1, 4 tbl.1, available
at http://www.biomedcentral.com/1741-7015/8/83.
vi

Id.

vii

Volker Wagner et al., The Emerging Nanomedicine Landscape, 24 NATURE BIOTECHNOLOGY 1211,
1214 tbl.2 (2006).
viii

Id.

ix

Id. at 1215 tbl.2.

x

Id.

xi

Original NDA was approved December 31, 1993. Subsequent NDAs have been approved and the
drug formulation based on the original NDA was discontinued. Patent information reflects currently active
formulation and NDA for Tricor.
xii

Rakesh K. Jain & Triantafyllos Stylianopoulos, Delivering Nanomedicine to Solid Tumors, 7
NATURE REVS. CLINICAL ONCOLOGY 653, 654 tbl.1 (2010).
Id.

xiv
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